AB 2300: Medical devices: Di-(2-ethylhexyl) phthalate (DEHP).
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2024-09-25
Current Status:
Passed
(2024-09-25: Chaptered by Secretary of State - Chapter 562, Statutes of 2024.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or childcare article that contains, among other things, Di-(2-ethylhexyl) phthalate (DEHP) in concentrations exceeding 0.1%.
This bill would, commencing January 1, 2030, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous solution containers made with intentionally added DEHP, as defined. The bill would extend the deadline to January 1, 2032, for a person or entity who has a pending United States Food and Drug Administration approval or who does not have adequate equipment to manufacture the DEHP-free intravenous solution container and who meets other specified requirements, including providing prescribed notices to consumers. The bill would also, commencing January 1, 2035, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous tubing made with intentionally added DEHP. The bill would prohibit a person or entity from manufacturing, selling, or distributing in commerce intravenous tubing or intravenous solution containers containing unintentionally added DEHP, as defined. The bill would prohibit a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates.
Existing law prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or childcare article that contains, among other things, Di-(2-ethylhexyl) phthalate (DEHP) in concentrations exceeding 0.1%.
This bill would, commencing January 1, 2030, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous solution containers made with intentionally added DEHP, as defined. The bill would extend the deadline to January 1, 2032, for a person or entity who has a pending United States Food and Drug Administration approval or who does not have adequate equipment to manufacture the DEHP-free intravenous solution container and who meets other specified requirements, including providing prescribed notices to consumers. The bill would also, commencing January 1, 2035, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous tubing made with intentionally added DEHP. The bill would prohibit a person or entity from manufacturing, selling, or distributing in commerce intravenous tubing or intravenous solution containers containing unintentionally added DEHP, as defined. The bill would prohibit a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates.
Existing law prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or childcare article that contains, among other things, Di-(2-ethylhexyl) phthalate (DEHP) in concentrations exceeding 0.1%.
This bill would, commencing January 1, 2030, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous solution containers made with intentionally added DEHP, as defined. The bill would extend the deadline to January 1, 2032, for a person or entity who has a pending United States Food and Drug Administration approval or who does not have adequate equipment to manufacture the DEHP-free intravenous solution container and who meets other specified requirements, including providing prescribed notices to consumers. The bill would also, commencing January 1, 2035, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous tubing made with intentionally added DEHP. The bill would prohibit a person or entity from manufacturing, selling, or distributing in commerce intravenous tubing or intravenous solution containers containing unintentionally added DEHP, as defined. The bill would prohibit a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates.
Existing law prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or childcare article that contains, among other things, Di-(2-ethylhexyl) phthalate (DEHP) in concentrations exceeding 0.1%.
This bill would, commencing January 1, 2026, 2030, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous solution containers made with intentionally added DEHP. DEHP, as defined. The bill would, would also, commencing January 1, 2031, 2035, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions. DEHP. The bill would prohibit a person or entity from manufacturing, selling, or distributing in commerce intravenous tubing or intravenous solution containers containing unintentionally added DEHP, as defined. The bill would prohibit a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates.
Existing law prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or childcare article that contains, among other things, Di-(2-ethylhexyl) phthalate (DEHP) in concentrations exceeding 0.1%.
This bill would, commencing January 1, 2026, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous solution containers made with intentionally added DEHP. The bill would, commencing January 1, 2031, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California certain intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions. The bill would prohibit a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates.
Existing law prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or childcare article that contains, among other things, Di-(2-ethylhexyl) phthalate (DEHP) in concentrations exceeding 0.1%.
This bill would, commencing January 1, 2026, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution containers made with intentionally added DEHP. The bill would, commencing January 1, 2031, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions. The bill would prohibit a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates.
Existing law prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or childcare article that contains, among other things, Di-(2-ethylhexyl) phthalate (DEHP) in concentrations exceeding 0.1%.
This bill would, commencing January 1, 2026, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution containers made with intentionally added DEHP. The bill would, commencing January 1, 2031, prohibit a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions. The bill would prohibit a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates.
The Legislature finds and declares all of the following:
(a)Di(2-ethylhexyl) phthalate (DEHP) and other ortho-phthalates are toxic chemicals and can have negative impacts on human health as determined by the United States Food and Drug Administration, the United States Environmental Protection Agency, or the Office of Environmental Health Hazard Assessment within the California Environmental Protection Agency.
(b)They are used primarily to produce flexibility in plastics, mainly polyvinyl chloride (PVC).
(c)This includes DEHP, the most common plasticizer used in medical devices, including intravenous solution containers (IV bags) and IV tubing.
(d)Over the course of its shelf life, DEHP leaches out of the plastic into the solution being held in the container.
(e)DEHP is classified as an endocrine-disrupting compound, meaning it can interfere with the hormonal system in humans and animals. It can mimic or block the actions of hormones, leading to adverse effects on reproductive health, development, and metabolism.
(f)Studies have suggested a potential link between DEHP exposure and certain types of cancer, including breast, liver, lung, and testicular cancer. The United States Environmental Protection Agency (EPA) has determined that DEHP is a probable human carcinogen, and it is included on the Proposition 65 list of chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
(g)DEHP exposure has been associated with adverse effects on reproductive organs and fertility. It can disrupt normal reproductive development, reduce sperm quality, and affect hormone levels in both males and females.
(h)DEHP is metabolized in the liver and can accumulate in the body over time. Prolonged exposure to high levels of DEHP has been shown to cause liver and kidney damage in animal studies.
(i)Inhalation or ingestion of DEHP can cause respiratory irritation and allergic reactions in some individuals, particularly those with preexisting respiratory conditions or sensitivities.
(j)While some major hospital systems use IV bags made with alternatives to DEHP, approximately 70 percent of California hospitals are buying and using IV bags made with DEHP.
(k)DEHP dosed at varying concentrations in cell culture studies has been linked to potential multidrug resistance in breast cancer cells that may inhibit the effectiveness of breast cancer drugs.
(l)Triple-negative breast cancer cells dosed in culture with DEHP have been potentially linked to multidrug resistance, inhibiting the apoptosis mechanism induced by breast cancer drugs such as tamoxifen and increasing cell proliferation in vitro. One proposed mechanism is that DEHP may serve as a mitogenic factor for estrogen receptor-positive breast cancer cells, potentially making them multidrug resistant.
109051.For purposes of this chapter, the following terms have the following definitions:
(a)DEHP means Di(2-ethylhexyl) phthalate.
(b)Intentionally added DEHP means DEHP that a manufacturer has intentionally added to an intravenous solution container or intravenous tubing product that has a functional or technical effect on the product.
(c)Intravenous solution containers means a container used to house medicine, fluid, or nutrition therapy that is intravenously administered to patients in a hospital, outpatient, or other health care facility.
(d)Intravenous tubing means any tubing used to intravenously administer fluids, medication, or nutrients directly to an adult, child, or infant.
(e)Ortho-phthalates means a class of chemicals that are esters of ortho-phthalic acid, including all of the following:
(1)Benzyl-butyl phthalate (BBP) 85-68-7.
(2)Dibutyl phthalate (DBP) 84-74-2.
(3)Dicyclohexyl phthalate (DCHP) 84-61-7.
(4)Di-(2-ethylhexyl) phthalate (DEHP) 117-81-7.
(5)Diethyl phthalate (DEP) 84-66-2.
(6)Di-isobutyl phthalate (DIBP) 84-69-5.
(7)Di-isodecyl phthalate (DIDP) 26761-40-0.
(8)Di-isononyl phthalate (DINP) 28553-12-0.
(9)Di-n-hexyl phthalate (DnHP) 84-75-3.
(10)Di-n-octyl phthalate (DNOP) 117-84-0.
(11)Di-n-pentyl (DnPP) phthalate 131-18-0.
(12)Diisoheptyl phthalate (DIHP) 71888-89-6.
(f)Unintentionally added DEHP means DEHP in an intravenous solution container or intravenous tubing product that is not used for functional or technical effect on the product.
109052.(a)Commencing January 1, 2030, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
(b)Commencing January 1, 2035, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous tubing made with intentionally added DEHP.
(c)A person or entity shall not replace DEHP, pursuant to this chapter, for revised or new products with other ortho-phthalates.
(d)An intravenous solution container or intravenous tubing product shall not have unintentionally added DEHP present at a quantity at or above 0.1 percent weight per weight (w/w).
(e)The following items, as described in Title 21 of the Code of Federal Regulations, are exempt from these provisions:
(1)Human blood collection and storage bags.
(2)Apheresis and cell therapy blood kits and bags, including integral tubing.
(f)A person or entity, due to pending United States Food and Drug Administration approval for the DEHP-free intravenous solution container or due to the manufacturer not having adequate equipment to manufacture the DEHP-free intravenous solution container, shall meet the requirement in subdivision (a) by January 1, 2032, if all of the following conditions are met:
(1)The person or entity notified its California customers, no later than July 1, 2025, that it has commenced development of the DEHP-free intravenous solution container to meet the requirements of this section.
(2)The person or entity provides notice to its customers and posts to its official internet website, no later than January 1, 2028, that it will not meet the deadline imposed pursuant to subdivision (a).
The Legislature finds and declares all of the following:
(a)Di(2-ethylhexyl) phthalate (DEHP) and other ortho-phthalates are toxic chemicals and can have negative impacts on human health as determined by the United States Food and Drug Administration, the United States Environmental Protection Agency, or the Office of Environmental Health Hazard Assessment within the California Environmental Protection Agency.
(b)They are used primarily to produce flexibility in plastics, mainly polyvinyl chloride (PVC).
(c)This includes DEHP, the most common plasticizer used in medical devices, including intravenous solution containers (IV bags) and IV tubing.
(d)Over the course of its shelf life, DEHP leaches out of the plastic into the solution being held in the container.
(e)DEHP is classified as an endocrine-disrupting compound, meaning it can interfere with the hormonal system in humans and animals. It can mimic or block the actions of hormones, leading to adverse effects on reproductive health, development, and metabolism.
(f)Studies have suggested a potential link between DEHP exposure and certain types of cancer, including breast, liver, lung, and testicular cancer. The United States Environmental Protection Agency (EPA) has determined that DEHP is a probable human carcinogen, and it is included on the Proposition 65 list of chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
(g)DEHP exposure has been associated with adverse effects on reproductive organs and fertility. It can disrupt normal reproductive development, reduce sperm quality, and affect hormone levels in both males and females.
(h)DEHP is metabolized in the liver and can accumulate in the body over time. Prolonged exposure to high levels of DEHP has been shown to cause liver and kidney damage in animal studies.
(i)Inhalation or ingestion of DEHP can cause respiratory irritation and allergic reactions in some individuals, particularly those with preexisting respiratory conditions or sensitivities.
(j)While some major hospital systems use IV bags made with alternatives to DEHP, approximately 70 percent of California hospitals are buying and using IV bags made with DEHP.
(k)DEHP dosed at varying concentrations in cell culture studies has been linked to potential multidrug resistance in breast cancer cells that may inhibit the effectiveness of breast cancer drugs.
(l)Triple-negative breast cancer cells dosed in culture with DEHP have been potentially linked to multidrug resistance, inhibiting the apoptosis mechanism induced by breast cancer drugs such as tamoxifen and increasing cell proliferation in vitro. One proposed mechanism is that DEHP may serve as a mitogenic factor for estrogen receptor-positive breast cancer cells, potentially making them multidrug resistant.
109051.For purposes of this chapter, the following terms have the following definitions:
(a)DEHP means Di(2-ethylhexyl) phthalate.
(b)Intentionally added DEHP means DEHP that a manufacturer has intentionally added to an intravenous solution container or intravenous tubing product that has a functional or technical effect on the product.
(c)Intravenous solution containers means a container used to house medicine, fluid, or nutrition therapy that is intravenously administered to patients in a hospital, outpatient, or other health care facility.
(d)Intravenous tubing means any tubing used to intravenously administer fluids, medication, or nutrients directly to an adult, child, or infant.
(e)Ortho-phthalates means a class of chemicals that are esters of ortho-phthalic acid, including all of the following:
(1)Benzyl-butyl phthalate (BBP) 85-68-7.
(2)Dibutyl phthalate (DBP) 84-74-2.
(3)Dicyclohexyl phthalate (DCHP) 84-61-7.
(4)Di-(2-ethylhexyl) phthalate (DEHP) 117-81-7.
(5)Diethyl phthalate (DEP) 84-66-2.
(6)Di-isobutyl phthalate (DIBP) 84-69-5.
(7)Di-isodecyl phthalate (DIDP) 26761-40-0.
(8)Di-isononyl phthalate (DINP) 28553-12-0.
(9)Di-n-hexyl phthalate (DnHP) 84-75-3.
(10)Di-n-octyl phthalate (DNOP) 117-84-0.
(11)Di-n-pentyl (DnPP) phthalate 131-18-0.
(12)Diisoheptyl phthalate (DIHP) 71888-89-6.
(f)Unintentionally added DEHP means DEHP in an intravenous solution container or intravenous tubing product that is not used for functional or technical effect on the product.
109052.(a)Commencing January 1, 2030, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
(b)Commencing January 1, 2035, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous tubing made with intentionally added DEHP.
(c)A person or entity shall not replace DEHP, pursuant to this chapter, for revised or new products with other ortho-phthalates.
(d)An intravenous solution container or intravenous tubing product shall not have unintentionally added DEHP present at a quantity at or above 0.1 percent weight per weight (w/w).
(e)The following items, as described in Title 21 of the Code of Federal Regulations, are exempt from these provisions:
(1)Human blood collection and storage bags.
(2)Apheresis and cell therapy blood kits and bags, including integral tubing.
(f)A person or entity, due to pending United States Food and Drug Administration approval for the DEHP-free intravenous solution container or due to the manufacturer not having adequate equipment to manufacture the DEHP-free intravenous solution container, shall meet the requirement in subdivision (a) by January 1, 2032, if all of the following conditions are met:
(1)The person or entity notified its California customers, no later than July 1, 2025, that it has commenced development of the DEHP-free intravenous solution container to meet the requirements of this section.
(2)The person or entity provides notice to its customers and posts to its official internet website, no later than January 1, 2028, that it will not meet the deadline imposed pursuant to subdivision (a).
The Legislature finds and declares all of the following:
(a)Di(2-ethylhexyl) phthalate (DEHP) and other ortho-phthalates are toxic chemicals and can have negative impacts on human health as determined by the United States Food and Drug Administration, the United States Environmental Protection Agency, or the Office of Environmental Health Hazard Assessment within the California Environmental Protection Agency.
(b)They are used primarily to produce flexibility in plastics, mainly polyvinyl chloride (PVC).
(c)This includes DEHP, the most common plasticizer used in medical devices, including intravenous solution containers (IV bags) and IV tubing.
(d)Over the course of its shelf life, DEHP leaches out of the plastic into the solution being held in the container.
(e)DEHP is classified as an endocrine-disrupting compound, meaning it can interfere with the hormonal system in humans and animals. It can mimic or block the actions of hormones, leading to adverse effects on reproductive health, development, and metabolism.
(f)Studies have suggested a potential link between DEHP exposure and certain types of cancer, including breast, liver, lung, and testicular cancer. The United States Environmental Protection Agency (EPA) has determined that DEHP is a probable human carcinogen, and it is included on the Proposition 65 list of chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
(g)DEHP exposure has been associated with adverse effects on reproductive organs and fertility. It can disrupt normal reproductive development, reduce sperm quality, and affect hormone levels in both males and females.
(h)DEHP is metabolized in the liver and can accumulate in the body over time. Prolonged exposure to high levels of DEHP has been shown to cause liver and kidney damage in animal studies.
(i)Inhalation or ingestion of DEHP can cause respiratory irritation and allergic reactions in some individuals, particularly those with preexisting respiratory conditions or sensitivities.
(j)While some major hospital systems use IV bags made with alternatives to DEHP, approximately 70 percent of California hospitals are buying and using IV bags made with DEHP.
(k)DEHP dosed at varying concentrations in cell culture studies has been linked to potential multidrug resistance in breast cancer cells that may inhibit the effectiveness of breast cancer drugs.
(l)Triple-negative breast cancer cells dosed in culture with DEHP have been potentially linked to multidrug resistance, inhibiting the apoptosis mechanism induced by breast cancer drugs such as tamoxifen and increasing cell proliferation in vitro. One proposed mechanism is that DEHP may serve as a mitogenic factor for estrogen receptor-positive breast cancer cells, potentially making them multidrug resistant.
109051.For purposes of this chapter, the following terms have the following definitions:
(a)DEHP means Di(2-ethylhexyl) phthalate.
(b)Intentionally added DEHP means DEHP that a manufacturer has intentionally added to an intravenous solution container or intravenous tubing product that has a functional or technical effect on the product.
(c)Intravenous solution containers means a container used to house medicine, fluid, or nutrition therapy that is intravenously administered to patients in a hospital, outpatient, or other health care facility.
(d)Intravenous tubing means any tubing used to intravenously administer fluids, medication, or nutrients directly to an adult, child, or infant.
(e)Ortho-phthalates means a class of chemicals that are esters of ortho-phthalic acid, including all of the following:
(1)Benzyl-butyl phthalate (BBP) 85-68-7.
(2)Dibutyl phthalate (DBP) 84-74-2.
(3)Dicyclohexyl phthalate (DCHP) 84-61-7.
(4)Di-(2-ethylhexyl) phthalate (DEHP) 117-81-7.
(5)Diethyl phthalate (DEP) 84-66-2.
(6)Di-isobutyl phthalate (DIBP) 84-69-5.
(7)Di-isodecyl phthalate (DIDP) 26761-40-0.
(8)Di-isononyl phthalate (DINP) 28553-12-0.
(9)Di-n-hexyl phthalate (DnHP) 84-75-3.
(10)Di-n-octyl phthalate (DNOP) 117-84-0.
(11)Di-n-pentyl (DnPP) phthalate 131-18-0.
(12)Diisoheptyl phthalate (DIHP) 71888-89-6.
(f)Unintentionally added DEHP means DEHP in an intravenous solution container or intravenous tubing product that is not used for functional or technical effect on the product.
109052.(a)Commencing January 1, 2030, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
(b)Commencing January 1, 2035, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous tubing made with intentionally added DEHP.
(c)A person or entity shall not replace DEHP, pursuant to this chapter, for revised or new products with other ortho-phthalates.
(d)An intravenous solution container or intravenous tubing product shall not have unintentionally added DEHP present at a quantity at or above 0.1 percent. percent weight per weight (w/w).
(e)The following items, as described in Title 21 of the Code of Federal Regulations, are exempt from these provisions:
(1)Human blood collection and storage bags.
(2)Apheresis and cell therapy blood kits and bags, including integral tubing.
(f)A person or entity, due to pending United States Food and Drug Administration approval for the DEHP-free intravenous solution container or due to the manufacturer not having adequate equipment to manufacture the DEHP-free intravenous solution container, shall meet the requirement in subdivision (a) by January 1, 2032, if all of the following conditions are met:
(1)The person or entity notified its California customers, no later than July 1, 2025, that it has commenced development of the DEHP-free intravenous solution container to meet the requirements of this section.
(2)The person or entity provides notice to its customers and posts to its official internet website, no later than January 1, 2028, that it will not meet the deadline imposed pursuant to subdivision (a).
The Legislature finds and declares all of the following:
(a)Di(2-ethylhexyl) phthalate (DEHP) and other ortho-phthalates are toxic chemicals. chemicals and can have negative impacts on human health as determined by the United States Food and Drug Administration, the United States Environmental Protection Agency, or the Office of Environmental Health Hazard Assessment within the California Environmental Protection Agency.
(b)They are used primarily to produce flexibility in plastics, mainly polyvinyl chloride (PVC).
(c)This includes DEHP, the most common plasticizer used in medical devices, including intravenous solution containers (IV bags) and IV tubing.
(d)Over the course of its shelf life, DEHP leaches out of the plastic into the solution being held in the container.
(e)DEHP is classified as an endocrine-disrupting compound, meaning it can interfere with the hormonal system in humans and animals. It can mimic or block the actions of hormones, leading to adverse effects on reproductive health, development, and metabolism.
(f)Studies have suggested a potential link between DEHP exposure and certain types of cancer, including breast, liver, lung, and testicular cancer. The United States Environmental Protection Agency (EPA) has determined that DEHP is a probable human carcinogen, and it is included on the Proposition 65 list of chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
(g)DEHP exposure has been associated with adverse effects on reproductive organs and fertility. It can disrupt normal reproductive development, reduce sperm quality, and affect hormone levels in both males and females.
(h)DEHP is metabolized in the liver and can accumulate in the body over time. Prolonged exposure to high levels of DEHP has been shown to cause liver and kidney damage in animal studies.
(i)Inhalation or ingestion of DEHP can cause respiratory irritation and allergic reactions in some individuals, particularly those with preexisting respiratory conditions or sensitivities.
(j)While some major hospital systems use IV bags made with nontoxic alternatives to DEHP, approximately 70 percent of California hospitals are buying and using toxic IV bags exposing patients directly to DEHP. IV bags made with DEHP.
(k)The leaching of DEHP from medical devices DEHP dosed at varying concentrations in cell culture studies has been linked to potential multidrug resistance in breast cancer cells, inhibiting cells that may inhibit the effectiveness of breast cancer drugs. This phenomenon has been observed at both high and low concentrations of DEHP, highlighting the potential impact of DEHP leaching on cancer treatment outcomes.
(l)Exposure to DEHP has been Triple-negative breast cancer cells dosed in culture with DEHP have been potentially linked to multidrug resistance in triple-negative breast cancer cells, resistance, inhibiting the apoptosis mechanism induced by breast cancer drugs such as tamoxifen and increasing cell proliferation. Moreover, DEHP has been suggested to proliferation in vitro. One proposed mechanism is that DEHP may serve as a mitogenic factor for estrogen receptor-positive breast cancer cells, potentially making them multidrug resistant.
109051.For purposes of this chapter, the following terms have the following definitions:
(a)DEHP means Di(2-ethylhexyl) phthalate.
(b)Intentionally added DEHP means DEHP that a manufacturer has intentionally added to a product and an intravenous solution container or intravenous tubing product that has a functional or technical effect on the product.
(c)Intravenous solution containers means a container used to house medicine, fluid, or nutrition therapy that is intravenously administered to patients in a hospital, outpatient, or other health care facility.
(d)Intravenous tubing means any tubing used to intravenously administer fluids, medication, or nutrients directly to an adult, child, or infant.
(e)Ortho-phthalates means a class of chemicals that are esters of ortho-phthalic acid, including all of the following:
(1)Benzyl-butyl phthalate (BBP) 85-68-7.
(2)Dibutyl phthalate (DBP) 84-74-2.
(3)Dicyclohexyl phthalate (DCHP) 84-61-7.
(4)Di-(2-ethylhexyl) phthalate (DEHP) 117-81-7.
(5)Diethyl phthalate (DEP) 84-66-2.
(6)Di-isobutyl phthalate (DIBP) 84-69-5.
(7)Di-isodecyl phthalate (DIDP) 26761-40-0.
(8)Di-isononyl phthalate (DINP) 28553-12-0.
(9)Di-n-hexyl phthalate (DnHP) 84-75-3.
(10)Di-n-octyl phthalate (DNOP) 117-84-0.
(11)Di-n-pentyl (DnPP) phthalate 131-18-0.
(12)Diisoheptyl phthalate (DIHP) 71888-89-6.
(f)Unintentionally added DEHP means DEHP in an intravenous solution container or intravenous tubing product that is not used for functional or technical effect on the product.
109052.(a)Commencing January 1, 2026, 2030, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
(b)Commencing January 1, 2031, 2035, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions. DEHP.
(c)A person or entity shall not replace DEHP, pursuant to this chapter, for revised or new products with other ortho-phthalates.
(d)An intravenous solution container or intravenous tubing product shall not have unintentionally added DEHP present at a quantity at or above 0.1 percent.
(d)(e)The following items, as described in Title 21 of the Code of Federal Regulations, are exempt from these provisions:
(1)Human blood collection and storage bags.
(2)Apheresis and cell therapy blood kits and bags, including integral tubing.
The Legislature finds and declares all of the following:
(a)Di(2-ethylhexyl) phthalate (DEHP) and other ortho-phthalates are toxic chemicals.
(b)They are used primarily to produce flexibility in plastics, mainly polyvinyl chloride (PVC).
(c)This includes DEHP, the most common plasticizer used in medical devices, including intravenous solution containers (IV bags) and IV tubing.
(d)Over the course of its shelf life, DEHP leaches out of the plastic into the solution being held in the container.
(e)DEHP is classified as an endocrine-disrupting compound, meaning it can interfere with the hormonal system in humans and animals. It can mimic or block the actions of hormones, leading to adverse effects on reproductive health, development, and metabolism.
(f)Studies have suggested a potential link between DEHP exposure and certain types of cancer, including breast, liver, lung, and testicular cancer. The United States Environmental Protection Agency (EPA) has determined that DEHP is a probable human carcinogen, and it is included on the Proposition 65 list of chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
(g)DEHP exposure has been associated with adverse effects on reproductive organs and fertility. It can disrupt normal reproductive development, reduce sperm quality, and affect hormone levels in both males and females.
(h)DEHP is metabolized in the liver and can accumulate in the body over time. Prolonged exposure to high levels of DEHP has been shown to cause liver and kidney damage in animal studies.
(i)Inhalation or ingestion of DEHP can cause respiratory irritation and allergic reactions in some individuals, particularly those with preexisting respiratory conditions or sensitivities.
(j)While some major hospital systems use IV bags made with nontoxic alternatives to DEHP, approximately 70 percent of California hospitals are buying and using toxic IV bags exposing patients directly to DEHP.
(k)The leaching of DEHP from medical devices at varying concentrations has been linked to multidrug resistance in breast cancer cells, inhibiting the effectiveness of breast cancer drugs. This phenomenon has been observed at both high and low concentrations of DEHP, highlighting the potential impact of DEHP leaching on cancer treatment outcomes.
(l)Exposure to DEHP has been linked to multidrug resistance in triple-negative breast cancer cells, inhibiting the apoptosis mechanism induced by breast cancer drugs such as tamoxifen and increasing cell proliferation. Moreover, DEHP has been suggested to serve as a mitogenic factor for estrogen receptor-positive breast cancer cells, potentially making them multidrug resistant.
109051.For purposes of this chapter, the following terms have the following definitions:
(a)DEHP means Di(2-ethylhexyl) phthalate.
(b)Intentionally added DEHP means DEHP that a manufacturer has intentionally added to a product and that has a functional or technical effect on the product.
(c)Intravenous solution containers means a container used to house medicine, fluid, or nutrition therapy that is intravenously administered to patients in a hospital, outpatient, or other health care facility.
(d)Intravenous tubing means any tubing used to administer fluids, medication, or nutrients directly to an adult, child, or infant.
(e)Ortho-phthalates means a class of chemicals that are esters of ortho-phthalic acid, including all of the following:
(1)Benzyl-butyl phthalate (BBP) 85-68-7.
(2)Dibutyl phthalate (DBP) 84-74-2.
(3)Dicyclohexyl phthalate (DCHP) 84-61-7.
(4)Di-(2-ethylhexyl) phthalate (DEHP) 117-81-7.
(5)Diethyl phthalate (DEP) 84-66-2.
(6)Di-isobutyl phthalate (DIBP) 84-69-5.
(7)Di-isodecyl phthalate (DIDP) 26761-40-0.
(8)Di-isononyl phthalate (DINP) 28553-12-0.
(9)Di-n-hexyl phthalate (DnHP) 84-75-3.
(10)Di-n-octyl phthalate (DNOP) 117-84-0.
(11)Di-n-pentyl (DnPP) phthalate 131-18-0.
(12)Diisoheptyl phthalate (DIHP) 71888-89-6.
109052.(a)Commencing January 1, 2026, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
(b)Commencing January 1, 2031, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions.
(c)A person or entity shall not replace DEHP, pursuant to this chapter, for revised or new products with other ortho-phthalates.
(d)The following items, as described in Title 21 of the Code of Federal Regulations, are exempt from these provisions:
(1)Human blood collection and storage bags.
(2)Apheresis and cell therapy blood kits and bags, including integral tubing.
The Legislature finds and declares all of the following:
(a)Di(2-ethylhexyl) phthalate (DEHP) and other ortho-phthalates are toxic chemicals.
(b)They are used primarily to produce flexibility in plastics, mainly polyvinyl chloride (PVC).
(c)This includes DEHP, the most common plasticizer used in medical devices, including intravenous solution containers (IV bags) and IV tubing.
(d)Over the course of its shelf life, DEHP leeches leaches out of the plastic into the solution being held in the container.
(e)DEHP is classified as an endocrine-disrupting compound, meaning it can interfere with the hormonal system in humans and animals. It can mimic or block the actions of hormones, leading to adverse effects on reproductive health, development, and metabolism.
(f)Studies have suggested a potential link between DEHP exposure and certain types of cancer, including breast, liver, lung, and testicular cancer. The United States Environmental Protection Agency (EPA) has determined that DEHP is a probable human carcinogen, and it is included on the Proposition 65 list of chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
(g)DEHP exposure has been associated with adverse effects on reproductive organs and fertility. It can disrupt normal reproductive development, reduce sperm quality, and affect hormone levels in both males and females.
(h)DEHP is metabolized in the liver and can accumulate in the body over time. Prolonged exposure to high levels of DEHP has been shown to cause liver and kidney damage in animal studies.
(i)Inhalation or ingestion of DEHP can cause respiratory irritation and allergic reactions in some individuals, particularly those with preexisting respiratory conditions or sensitivities.
(j)While some major hospital systems use IV bags made with nontoxic alternatives to DEHP, approximately 70 percent of California hospitals are buying and using toxic IV bags exposing patients directly to DEHP.
(k)The leaching of DEHP from medical devices at varying concentrations has been linked to multidrug resistance in breast cancer cells, inhibiting the effectiveness of breast cancer drugs. This phenomenon has been observed at both high and low concentrations of DEHP, highlighting the potential impact of DEHP leaching on cancer treatment outcomes.
(l)Exposure to DEHP has been linked to multidrug resistance in triple-negative breast cancer cells, inhibiting the apoptosis mechanism induced by breast cancer drugs such as tamoxifen and increasing cell proliferation. Moreover, DEHP has been suggested to serve as a mitogenic factor for estrogen receptor-positive breast cancer cells, potentially making them multidrug resistant.
109051.For purposes of this chapter, the following terms have the following definitions:
(a)DEHP means Di(2-ethylhexyl) phthalate.
(b)Intentionally added DEHP means DEHP that a manufacturer has intentionally added to a product and that has a functional or technical effect on the product.
(c)Intravenous solution containers means a container used to house medicine, fluid, or nutrition therapy that is intravenously delivered administered to patients in a hospital, outpatient, or other health care facility.
(d)Intravenous tubing means any tubing used to administer fluids, medication, or nutrients directly to an adult, child, or infant.
(e)Ortho-phthalates means a class of chemicals that are esters of ortho-phthalic acid, including all of the following:
(1)Benzyl-butyl phthalate (BBP) 85-68-7.
(2)Dibutyl phthalate (DBP) 84-74-2.
(3)Dicyclohexyl phthalate (DCHP) 84-61-7.
(4)Di-(2-ethylhexyl) phthalate (DEHP) 117-81-7.
(5)Diethyl phthalate (DEP) 84-66-2.
(6)Di-isobutyl phthalate (DIBP) 84-69-5.
(7)Di-isodecyl phthalate (DIDP) 26761-40-0.
(8)Di-isononyl phthalate (DINP) 28553-12-0.
(9)Di-n-hexyl phthalate (DnHP) 84-75-3.
(10)Di-n-octyl phthalate (DNOP) 117-84-0.
(11)Di-n-pentyl (DnPP) phthalate 131-18-0.
(12)Diisoheptyl phthalate (DIHP) 71888-89-6.
109052.(a)Commencing January 1, 2026, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
(b)Commencing January 1, 2031, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions.
(c)A person or entity shall not replace DEHP, pursuant to this chapter, for revised or new products with other ortho-phthalates.
The Legislature finds and declares all of the following:
(a)Di(2-ethylhexyl) phthalate (DEHP) and other ortho-phthalates are toxic chemicals.
(b)They are used primarily to produce flexibility in plastics, mainly polyvinyl chloride (PVC).
(c)This includes DEHP, the most common plasticizer used in medical devices, including intravenous solution containers (IV bags) and IV tubing.
(d)Over the course of its shelf life, DEHP leeches out of the plastic into the solution being held in the container.
(e)DEHP is classified as an endocrine-disrupting compound, meaning it can interfere with the hormonal system in humans and animals. It can mimic or block the actions of hormones, leading to adverse effects on reproductive health, development, and metabolism.
(f)Studies have suggested a potential link between DEHP exposure and certain types of cancer, including breast, liver, lung, and testicular cancer. The United States Environmental Protection Agency (EPA) has determined that DEHP is a probable human carcinogen, and it is included on the Proposition 65 list of chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
(g)DEHP exposure has been associated with adverse effects on reproductive organs and fertility. It can disrupt normal reproductive development, reduce sperm quality, and affect hormone levels in both males and females.
(h)DEHP is metabolized in the liver and can accumulate in the body over time. Prolonged exposure to high levels of DEHP has been shown to cause liver and kidney damage in animal studies.
(i)Inhalation or ingestion of DEHP can cause respiratory irritation and allergic reactions in some individuals, particularly those with preexisting respiratory conditions or sensitivities.
(j)While some major hospital systems use IV bags made with nontoxic alternatives to DEHP, approximately 70 percent of California hospitals are buying and using toxic IV bags exposing patients directly to DEHP.
(k)The leaching of DEHP from medical devices at varying concentrations has been linked to multidrug resistance in breast cancer cells, inhibiting the effectiveness of breast cancer drugs. This phenomenon has been observed at both high and low concentrations of DEHP, highlighting the potential impact of DEHP leaching on cancer treatment outcomes.
(l)Exposure to DEHP has been linked to multidrug resistance in triple-negative breast cancer cells, inhibiting the apoptosis mechanism induced by breast cancer drugs such as tamoxifen and increasing cell proliferation. Moreover, DEHP has been suggested to serve as a mitogenic factor for estrogen receptor-positive breast cancer cells, potentially making them multidrug resistant.
109051.For purposes of this chapter, the following terms have the following definitions:
(a)DEHP means Di(2-ethylhexyl) phthalate.
(b)Intentionally added DEHP means DEHP that a manufacturer has intentionally added to a product and that has a functional or technical effect on the product.
(c)Intravenous solution containers means a container used to house medicine, fluid, or nutrition therapy that is intravenously delivered to patients in a hospital, outpatient, or other health care facility.
(d)Intravenous tubing means any tubing used to administer fluids, medication, or nutrients directly to an adult, child, or infant.
(e)Ortho-phthalates means a class of chemicals that are esters of ortho-phthalic acid, including all of the following:
(1)Benzyl-butyl phthalate (BBP) 85-68-7.
(2)Dibutyl phthalate (DBP) 84-74-2.
(3)Dicyclohexyl phthalate (DCHP) 84-61-7.
(4)Di-(2-ethylhexyl) phthalate (DEHP) 117-81-7.
(5)Diethyl phthalate (DEP) 84-66-2.
(6)Di-isobutyl phthalate (DIBP) 84-69-5.
(7)Di-isodecyl phthalate (DIDP) 26761-40-0.
(8)Di-isononyl phthalate (DINP) 28553-12-0.
(9)Di-n-hexyl phthalate (DnHP) 84-75-3.
(10)Di-n-octyl phthalate (DNOP) 117-84-0.
(11)Di-n-pentyl (DnPP) phthalate 131-18-0.
(12)Diisoheptyl phthalate (DIHP) 71888-89-6.
109052.(a)Commencing January 1, 2026, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
(b)Commencing January 1, 2031, a person or entity shall not manufacture, sell, or distribute into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions.
(c)A person or entity shall not replace DEHP, pursuant to this chapter, for revised or new products with other ortho-phthalates.
|
Date
|
Status
|
|---|---|
| Sep 25, 2024 | Chaptered by Secretary of State - Chapter 562, Statutes of 2024. |
| Sep 25, 2024 | Approved by the Governor. |
| Sep 5, 2024 | Enrolled and presented to the Governor at 4 p.m. |
| Aug 27, 2024 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 74. Noes 0.). |
| Aug 27, 2024 | Assembly Rule 77 suspended. |
| Aug 26, 2024 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after August 28 pursuant to Assembly Rule 77. |
| Aug 26, 2024 | Read third time. Passed. Ordered to the Assembly. (Ayes 39. Noes 0.). |
| Aug 5, 2024 | Read second time. Ordered to third reading. |
| Jul 3, 2024 | From committee: Do pass. (Ayes 7. Noes 0.) (July 3). |
| Jun 27, 2024 | Read second time and amended. Re-referred to Com. on E.Q. |
| Jun 26, 2024 | From committee: Amend, and do pass as amended and re-refer to Com. on E.Q. (Ayes 11. Noes 0.) (June 26). |
| Jun 5, 2024 | Referred to Coms. on HEALTH and E.Q. |
| May 23, 2024 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 22, 2024 | Read third time. Passed. Ordered to the Senate. (Ayes 58. Noes 1. Page 5553.) |
| May 21, 2024 | Assembly Rule 69(d) suspended. (Page 5352.) |
| May 20, 2024 | Read third time and amended. Ordered to third reading. (Ayes 55. Noes 11. Page 5292.) |
| Apr 25, 2024 | Read second time. Ordered to third reading. |
| Apr 24, 2024 | From committee: Do pass. (Ayes 5. Noes 1.) (April 23). |
| Apr 3, 2024 | From committee: Do pass and re-refer to Com. on E.S. & T.M. (Ayes 10. Noes 1.) (April 2). Re-referred to Com. on E.S. & T.M. |
| Apr 2, 2024 | Re-referred to Com. on HEALTH. |
| Apr 1, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 7, 2024 | Re-referred to Com. on HEALTH. |
| Mar 6, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Feb 26, 2024 | Referred to Coms. on HEALTH and E.S. & T.M. |
| Feb 13, 2024 | From printer. May be heard in committee March 14. |
| Feb 12, 2024 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 27, 2024 | AB 2300 Wilson Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 26, 2024 | Assembly 3rd Reading AB2300 Wilson et al. By Min | Senate Floor |
Passed |
|
| Jul 3, 2024 | Do pass | Senate Standing Committee on Environmental Quality |
Passed |
|
| Jun 26, 2024 | Do pass as amended, but first amend, and re-refer to the Committee on [Environmental Quality] | Senate Standing Committee on Health |
Passed |
|
| May 22, 2024 | AB 2300 Wilson Assembly Third Reading | Assembly Floor |
Passed |
|
| May 20, 2024 | AB 2300 Wilson Assembly Third Reading Amendment Set #1 | Assembly Floor |
Passed |
|
| Apr 23, 2024 | Do pass. | Assembly Standing Committee on Environmental Safety and Toxic Materials |
Passed |
|
| Apr 2, 2024 | Do pass and be re-referred to the Committee on [Environmental Safety and Toxic Materials] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Access Reproductive Justice | ** Support | |
| Advanced Medical Technology Association | ** Against | |
| Alliance of Nurses for Healthy Environments | ** Support | |
| American College Of Obstetricians And Gynecologists District Ix | ** Support | |
| Asian Americans Advancing Justice Southern California | ** Support | |
| Association Of Regional Center Agencies | ** Support | |
| A Voice for Choice Advocacy | ** Support | |
| B. Braun Medical, Inc. | ** Support | |
| Breast Cancer Prevention Partners | ** Support | |
| Buen Vecino | ** Support | |
| California Black Health Network | ** Support | |
| California Health Coalition Advocacy | ** Support | |
| California Nurses for Environmental Health and Justice | ** Support | |
| California Pan-Ethnic Health Network | ** Support | |
| California Public Interest Research Group | ** Support | |
| Center for Community Action and Environmental Justice | ** Support | |
| Center For Environmental Health | ** Support | |
| Cerus Corporation | ** Against | |
| cleanearth4kids.org | ** Support | |
| clean production action | ** Support | |
| Clean Water Action | ** Support | |
| Courage California | ** Support | |
| Defend Our Health | ** Support | |
| Educate. Advocate. | ** Support | |
| Fresenius Kabi | ** Support | |
| Health Care Without Harm | ** Support | |
| Health Equity for African American's League | ** Support | |
| Healthy Contra Costa | ** Support | |
| Keep A Breast | ** Support | |
| Latino Coalition for a Healthy California | ** Support | |
| Made Safe | ** Support | |
| Mixteco Indigena Community Organizing Project | ** Support | |
| National Association of Environmental Medicine | ** Support | |
| National Stewardship of Action Council | ** Support | |
| National Union Of Healthcare Workers | ** Support | |
| Northern California Center for Well-being | ** Support | |
| Plastic Pollution Coalition | ** Support | |
| PRC - Black Leadership Council | ** Support | |
| Public Health Advocates | ** Support | |
| San Francisco Bay Physicians for Social Responsibility | ** Support | |
| Science and Environmental Health Network | ** Support | |
| Sharp Healthcare | ** Support | |
| The Last Beach Cleanup | ** Support | |
| Urban Strategies Council | ** Support | |
| We ACT For Environmental Justice | ** Support | |
| Western Center on Law & Poverty, INC. | ** Support | |
| Womens Voices for the Earth | ** Support | |
| Young Invincibles | ** Support |
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 2300
Author:(Wilson)
As Amended Ver:June 27, 2024
Majority vote
SUMMARY
Prohibits, beginning January 1, 2030, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution (IV) containers made with intentionally added di-(2-ethylhexyl) phthalate (DEHP). Additionally prohibits, beginning January 1, 2035, a person or entity from manufacturing, selling or distributing into commerce IV tubing made with intentionally added DEHP. Prohibits an IV solution container or IV tubing product from having unintentionally added DEHP present at a quantity at or above 0.1%. Exempts from the provisions of this bill human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing.
Senate Amendments
Clarify that an IV solution container or IV tubing product shall not have unintentionally added DEHP present at a quantity at or above 0.1% weight per weight. Extend the deadline for compliance with this bill to January 1, 2032, for a person or entity who has a pending United States Food and Drug Administration approval or who does not have adequate equipment to manufacture the DEHP-free intravenous solution container if all of the following conditions are met: 1) the person or entity has notified its California customers, no later than July 1, 2025, that it has commenced development of the DEHP-free intravenous solution container to meet the requirements of this section; 2) the person or entity provides notice to its customers and posts to its official internet website, no later than January 1, 2028 that it will not meet the January 1, 2030 deadline imposed by this bill.
COMMENTS
DEHP. DEHP belongs to a family of chemicals called phthalates, which are added to some plastics to make them flexible. An article, published in Additives for Polymers in 2017, estimated the global consumption of DEHP at 3.07 million tons the previous year. DEHP has been listed on the California Office of Health Hazard Assessment (OEHHA)'s Proposition 65 list as causing cancer since 1988 and a developmental and male reproductive toxicant since 2003. In 1988, the U.S. Environmental Protection Agency listed DEHP as a probable carcinogen.
DEHP and healthcare. DEHP is present in medical devices such as catheters, disposable gloves IV containers, IV tubing, and blood bags.
European Union (EU) ban. In 2018, the EU added DEHP to their REACH (Registration, Evaluation, Authorization and Restriction of Chemical) Authorization list. As a result of inclusion on the REACH list, DEHP is required to be phased out of medical devices. Per the EU's November 2023 regulation, DEHP cannot be used in medical devices starting July 1, 2030, unless manufacturers apply for authorization before January 1, 2029. Authorization applications will be evaluated before approval.
Alternatives in the market. At least four major manufactures of IV bags in the US already supply DEHP-free IV solution containers or IV sets: B. Braun Medical, Fresenius Kabi, Baxter, and ICU Medical. Kaiser reports on their website that they have successfully phased out IV solution bags that contain DEHP. It is unclear how many other healthcare systems in California have implemented or started to implement similar changes.
According to the Author
According to the author, "As a recent patient of the medical care system, I have first-hand knowledge related to the need for multiple infusions, with long durations, through medicines administered from IV bags. Each time you are potentially being exposed to a toxic material simply because we haven't passed a law to ban this toxic material. There are alternatives, they are currently being used, and they aren't more expensive. The State decided to ban the use of DEHP in kids' toys, I think it is time to ban this from medical containers that allow leaching directly into our bodies- when we are most vulnerable. People should be focused on their healthcare, not whether the very life-saving procedure is exposing them to cancer-causing chemicals and other terrible health impacts."
Arguments in Support
Breast Cancer Prevention Partners and California Black Health Network, cosponsors of this bill, state that research indicates that DEHP promotes drug resistance and inhibits the effectiveness of breast cancer drugs; interferes with the ability of chemotherapies to fight breast cancer, and that patients with higher levels of DEHP in their system had higher rates of relapse and mortality. California's standards for medical devices need to be higher. DEHP is harmful throughout its entire life cycle, from manufacturing to disposal, and it has serious impacts that extend beyond human health. Non-DEHP containers and tubing have been available for decades. The cosponsors conclude that just as DEHP is no longer legally allowed in make-up and personal care products, toys and other children's products sold in California, it is time for DEHP to be eliminated from these medical devices.
Arguments in Opposition
There is no known opposition on file.
FISCAL COMMENTS
None.
VOTES:
ASM HEALTH: 10-1-5
YES: Bonta, Aguiar-Curry, Arambula, Wendy Carrillo, Haney, Maienschein, Rodriguez, Santiago, Schiavo, Weber
NO: Jones-Sawyer
ABS, ABST OR NV: Waldron, Flora, McCarty, Joe Patterson, Sanchez
ASM ENVIRONMENTAL SAFETY AND TOXIC MATERIALS: 5-1-1
YES: Garcia, Connolly, McKinnor, Papan, Reyes
NO: Hoover
ABS, ABST OR NV: Ta
ASSEMBLY FLOOR: 58-1-21
YES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Juan Carrillo, Wendy Carrillo, Connolly, Mike Fong, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO: Dixon
ABS, ABST OR NV: Calderon, Cervantes, Chen, Megan Dahle, Davies, Essayli, Flora, Vince Fong, Friedman, Gallagher, Holden, Hoover, Lackey, Mathis, Jim Patterson, Joe Patterson, Luz Rivas, Sanchez, Ta, Waldron, Wallis
SENATE FLOOR: 40-0-0
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Jones, Laird, Limón, McGuire, Menjivar, Min, Newman, Nguyen, Niello, Ochoa Bogh, Padilla, Portantino, Roth, Rubio, Seyarto, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
ASSEMBLY FLOOR: 55-11-14
YES: Addis, Aguiar-Curry, Alvarez, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Connolly, Mike Fong, Friedman, Garcia, Gipson, Grayson, Haney, Hart, Holden, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO: Alanis, Davies, Dixon, Essayli, Flora, Vince Fong, Gallagher, Hoover, Joe Patterson, Sanchez, Wallis
ABS, ABST OR NV: Arambula, Bains, Cervantes, Chen, Megan Dahle, Gabriel, Lackey, Mathis, Muratsuchi, Stephanie Nguyen, Jim Patterson, Luz Rivas, Ta, Waldron
UPDATED
VERSION: June 27, 2024
CONSULTANT: Eliza Brooks / HEALTH / (916) 319-2097 FN: 0003820
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 2300
Author:(Wilson)
As Amended Ver:June 27, 2024
Majority vote
SUMMARY
Prohibits, beginning January 1, 2030, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution (IV) containers made with intentionally added di-(2-ethylhexyl) phthalate (DEHP). Additionally prohibits, beginning January 1, 2035, a person or entity from manufacturing, selling or distributing into commerce IV tubing made with intentionally added DEHP. Prohibits an IV solution container or IV tubing product from having unintentionally added DEHP present at a quantity at or above 0.1%. Exempts from the provisions of this bill human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing.
Senate Amendments
Clarify that an IV solution container or IV tubing product shall not have unintentionally added DEHP present at a quantity at or above 0.1% weight per weight. Extend the deadline for compliance with this bill to January 1, 2032, for a person or entity who has a pending United States Food and Drug Administration approval or who does not have adequate equipment to manufacture the DEHP-free intravenous solution container if all of the following conditions are met: 1) the person or entity has notified its California customers, no later than July 1, 2025, that it has commenced development of the DEHP-free intravenous solution container to meet the requirements of this section; 2) the person or entity provides notice to its customers and posts to its official internet website, no later than January 1, 2028 that it will not meet the January 1, 2030 deadline imposed by this bill.
COMMENTS
DEHP. DEHP belongs to a family of chemicals called phthalates, which are added to some plastics to make them flexible. An article, published in Additives for Polymers in 2017, estimated the global consumption of DEHP at 3.07 million tons the previous year. DEHP has been listed on the California Office of Health Hazard Assessment (OEHHA)'s Proposition 65 list as causing cancer since 1988 and a developmental and male reproductive toxicant since 2003. In 1988, the U.S. Environmental Protection Agency listed DEHP as a probable carcinogen.
DEHP and healthcare. DEHP is present in medical devices such as catheters, disposable gloves IV containers, IV tubing, and blood bags.
European Union (EU) ban. In 2018, the EU added DEHP to their REACH (Registration, Evaluation, Authorization and Restriction of Chemical) Authorization list. As a result of inclusion on the REACH list, DEHP is required to be phased out of medical devices. Per the EU's November 2023 regulation, DEHP cannot be used in medical devices starting July 1, 2030, unless manufacturers apply for authorization before January 1, 2029. Authorization applications will be evaluated before approval.
Alternatives in the market. At least four major manufactures of IV bags in the US already supply DEHP-free IV solution containers or IV sets: B. Braun Medical, Fresenius Kabi, Baxter, and ICU Medical. Kaiser reports on their website that they have successfully phased out IV solution bags that contain DEHP. It is unclear how many other healthcare systems in California have implemented or started to implement similar changes.
According to the Author
According to the author, "As a recent patient of the medical care system, I have first-hand knowledge related to the need for multiple infusions, with long durations, through medicines administered from IV bags. Each time you are potentially being exposed to a toxic material simply because we haven't passed a law to ban this toxic material. There are alternatives, they are currently being used, and they aren't more expensive. The State decided to ban the use of DEHP in kids' toys, I think it is time to ban this from medical containers that allow leaching directly into our bodies- when we are most vulnerable. People should be focused on their healthcare, not whether the very life-saving procedure is exposing them to cancer-causing chemicals and other terrible health impacts."
Arguments in Support
Breast Cancer Prevention Partners and California Black Health Network, cosponsors of this bill, state that research indicates that DEHP promotes drug resistance and inhibits the effectiveness of breast cancer drugs; interferes with the ability of chemotherapies to fight breast cancer, and that patients with higher levels of DEHP in their system had higher rates of relapse and mortality. California's standards for medical devices need to be higher. DEHP is harmful throughout its entire life cycle, from manufacturing to disposal, and it has serious impacts that extend beyond human health. Non-DEHP containers and tubing have been available for decades. The cosponsors conclude that just as DEHP is no longer legally allowed in make-up and personal care products, toys and other children's products sold in California, it is time for DEHP to be eliminated from these medical devices.
Arguments in Opposition
There is no known opposition on file.
FISCAL COMMENTS
None.
VOTES:
ASM HEALTH: 10-1-5
YES: Bonta, Aguiar-Curry, Arambula, Wendy Carrillo, Haney, Maienschein, Rodriguez, Santiago, Schiavo, Weber
NO: Jones-Sawyer
ABS, ABST OR NV: Waldron, Flora, McCarty, Joe Patterson, Sanchez
ASM ENVIRONMENTAL SAFETY AND TOXIC MATERIALS: 5-1-1
YES: Garcia, Connolly, McKinnor, Papan, Reyes
NO: Hoover
ABS, ABST OR NV: Ta
ASSEMBLY FLOOR: 58-1-21
YES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Juan Carrillo, Wendy Carrillo, Connolly, Mike Fong, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO: Dixon
ABS, ABST OR NV: Calderon, Cervantes, Chen, Megan Dahle, Davies, Essayli, Flora, Vince Fong, Friedman, Gallagher, Holden, Hoover, Lackey, Mathis, Jim Patterson, Joe Patterson, Luz Rivas, Sanchez, Ta, Waldron, Wallis
ASSEMBLY FLOOR: 55-11-14
YES: Addis, Aguiar-Curry, Alvarez, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Connolly, Mike Fong, Friedman, Garcia, Gipson, Grayson, Haney, Hart, Holden, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO: Alanis, Davies, Dixon, Essayli, Flora, Vince Fong, Gallagher, Hoover, Joe Patterson, Sanchez, Wallis
ABS, ABST OR NV: Arambula, Bains, Cervantes, Chen, Megan Dahle, Gabriel, Lackey, Mathis, Muratsuchi, Stephanie Nguyen, Jim Patterson, Luz Rivas, Ta, Waldron
UPDATED
VERSION: June 27, 2024
CONSULTANT: Eliza Brooks / HEALTH / (916) 319-2097 FN: 0003820
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 2300 |
THIRD READING
Bill No: AB 2300
Author: Wilson (D), et al.
Amended: 6/27/24 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 6/26/24
AYES: Roth, Nguyen, Glazer, Gonzalez, Grove, Hurtado, Limón, Menjivar, Rubio, Smallwood-Cuevas, Wiener
SENATE ENVIRONMENTAL QUALITY COMMITTEE: 7-0, 7/3/24
AYES: Allen, Dahle, Gonzalez, Hurtado, Menjivar, Nguyen, Skinner
ASSEMBLY FLOOR: 58-1, 5/22/24 - See last page for vote
SUBJECT: Medical devices: Di-(2-ethylhexyl) phthalate (DEHP)
SOURCE: American College of Obstetricians and Gynecologists District IX
Breast Cancer Prevention Partners
California Black Health Network
DIGEST:
Prohibits the manufacture, sale, or distribution of intravenous solution containers and tubing made with intentionally added Di-(2-ethylhexyl) phthalate.
ANALYSIS:
Existing law:
- Prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or childcare article that contains, among other things, Di-(2-ethylhexyl) phthalate (DEHP) in concentrations exceeding 0.1%. Prohibits manufacturers from replacing phthalates in these products with specified carcinogens, or substances listed as known or likely carcinogens, known to be human carcinogens, likely to be human carcinogens, or suggestive of being human carcinogens, or reproductive toxicants that cause birth defects, reproductive harm, or developmental harm. [Health and Safety Code (HSC) §108937 and §108939]
- Prohibits, commencing January 1, 2025, a person or entity from manufacturing any cosmetic that contains intentionally added DEHP. [HSC §108980]
This bill:
- Prohibits the manufacture, sale, or distribution of intravenous (IV) solution containers made with intentionally added DEHP beginning January 1, 2030 and IV tubing made with intentionally added DEHP beginning January 1, 2035.
- Prohibits the replacement of DEHP in these products, for revised or new products, with other ortho-phthalates.
- Prohibits an IV solution container or tubing product from having unintentionally added DEHP present at or above 0.1% weight per weight.
- Provides for an extension to the 2030 date for IV solution containers to January 1, 2032 due to pending U.S. Food and Drug Administration (FDA) approval for the DEHP-free container or due to a manufacturer having inadequate equipment to manufacture the DEHP-free container, if:
- The manufacturer notified its California customers by July 1, 2025 that it has commenced development of the DEHP-free solution container; and,
- The manufacturer provides notice to its customers and posts to its website, by January 1, 2028, that it will not meet the 2030 deadline.
- Exempts human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing, from the prohibitions contained in this bill.
Comments
- Author’s statement. According to the author, as a recent patient of the medical care system, I have first-hand knowledge related to the need for multiple infusions, with long durations, through medicines administered from IV bags. Each time, you are potentially being exposed to a toxic material simply because we haven’t passed a law to ban this toxic material. There are alternatives; they are currently being used and aren’t more expensive. The State decided to ban the use of DEHP in kids' toys and cosmetics; I think it is time to ban this from medical containers that allow leaching directly into our bodies- when we are most vulnerable. People should be focused on their healthcare, not whether the very life-saving procedure is exposing them to cancer and other terrible health impacts.
- Background. DEHP belongs to a family of chemicals called phthalates, and is widely considered to have toxic effects: the U.S. Department of Health and Human Services classified DEHP as reasonably anticipated to be a human carcinogen; the U.S. Environmental Protection Agency has determined that DEHP is a probable human carcinogen; and, the International Agency for Research on Cancer has classified DEHP as possibly carcinogenic to humans. In September 2002, the federal Agency for Toxics Substances and Disease Registry issued a Public Health Statement regarding DEHP because it was considered to be a hazardous substance. According to the statement, DEHP is a colorless liquid with almost no odor that is commonly added to plastics to make them flexible. DEHP does not evaporate easily, and little will be present in the air even near sources of production. It is used in many products that are made from plastic, but especially in polyvinyl chloride (PVC) or vinyl. DEHP is on California’s Proposition 65 list because it can cause cancer and birth defects or other reproductive harm. According to the Proposition 65 Warnings Website, in the past, DEHP was one of the phthalates most frequently used in plastic products, but its use has decreased in recent years. DEHP is still used in various types of plastic consumer products, including: shower curtains, furniture and automobile upholstery, garden hoses, floor tiles, coverings on wires and cables, rainwear, shoes, lunchboxes, binders, and backpacks, plastic food packaging materials, medical devices and equipment (including some types of blood and intravenous solution bags, tubing for dialysis, feeding tubes, oxygen masks, and surgical gloves). California law prohibits the manufacture, sale, or distribution of children’s toys and childcare articles containing DEHP at levels greater than 0.1%. Federal law has a similar prohibition.
- DEHP in medical devices. According to a 2015 review published in the Transfusion Medicine Reviews Journal, PVC is used in many medical devices because it shows optimal inertness, durability, and resistance to heat and chemicals. However, PVC needs to be plasticized, and DEHP has been the most common plasticizer to produce flexibility. DEHP has been found to leach out from the containers and devices, causing toxic effects, demonstrated mainly in rodents. In September 2002, the FDA issued a Guidance for Industry recommending that manufacturers label medical devices made with DEHP and manufacturers consider replacing PVC containing DEHP with alternative materials, stating that devices used in Neonatal Intensive Care Units (NICUs) should be a primary focus. A December 2012 Guidance for Industry states that because the FDA determined that there is evidence that exposure to DEHP from pharmaceuticals presents a potential risk of developmental and reproductive toxicity, and safer alternatives are available, the FDA recommends the use of DEHP be avoided as excipients in regulated drug and biologic products. The first study to document the amount of phthalates leached from various medical supplies and associated exposures was published in May 2023. The study found that DEHP was the major phthalate found in 99% of the samples analyzed, with the highest amount leached from respiratory support devices. DEHP was also found at notable concentrations in products labeled as “DEHP-free.” However, the amounts of DEHP leached from those products were lower than those of other medical devices. Direct exposure to phthalates from the use of medical devices and first aid supplies and dermal intake from the use of creams/lotions were also calculated. The highest DEHP exposure dose was determined from the use of cannula for neonates. The study authors concluded by stating that efforts should be made to regulate phthalates in medical devices, and the safety of other alternative plasticizers that are currently used as replacements should be examined. The chemical safety of medical devices is of vital importance to help safeguard the health of patients, especially newborns, and efforts are needed to address the critical issue urgently.
- Prior legislation. AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) prohibits, beginning January 1, 2025, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing specified intentionally added ingredients, including DEHP. AB 1108 (Ma, Chapter 672, Statutes of 2008) prohibits the use of DEHP and other phthalates in toys and childcare products.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 7/12/24)
American College of Obstetricians and Gynecologists District IX (co-source)
Breast Cancer Prevention Partners (co-source)
California Black Health Network (co-source)
A Voice for Choice Advocacy
Access Reproductive Justice
Alliance of Nurses for Healthy Environments
Asian Americans Advancing Justice Southern California
Association of Regional Center Agencies
B. Braun Medical, Inc.
Buen Vecino
California Health Coalition Advocacy
California Nurses for Environmental Health and Justice
California Pan-Ethnic Health Network
California Public Interest Research Group
Center for Community Action and Environmental Justice
Center for Environmental Health
Clean Production Action
Clean Water Action
Cleanearth4kids.org
Courage California
Defend Our Health
Educate. Advocate.
Fresenius Kabi
Health Care Without Harm
Health Equity for African American’s League
Healthy Contra Costa
Keep a Breast
Latino Coalition for a Healthy California
Made Safe
Mixteco Indigena Community Organizing Project
National Association of Environmental Medicine
National Stewardship of Action Council
National Union of Healthcare Workers
Northern California Center for Well-Being
Plastic Pollution Coalition
PRC & Black Leadership Council
Public Health Advocates
San Francisco Bay Physicians for Social Responsibility
Science and Environmental Health Network
Sharp Healthcare
The Last Beach Cleanup
Urban Strategies Council
Western Center on Law & Poverty, Inc.
Women’s Voices for the Earth
Young Invincibles
OPPOSITION: (Verified 7/12/24)
None received
ARGUMENTS IN SUPPORT: Breast Cancer Prevention Partners, California Black Health Network, and the American College of Obstetricians and Gynecologists (cosponsors of this bill) state that research indicates that DEHP promotes drug resistance and inhibits the effectiveness of breast cancer drugs; interferes with the ability of chemotherapies to fight breast cancer, and that patients with higher levels of DEHP in their system had higher rates of relapse and mortality. California's standards for medical devices needs to be higher. DEHP is harmful throughout its entire life cycle, from manufacturing to disposal, and it has serious impacts that extend beyond human health. Non-DEHP containers and tubing have been available for decades. The cosponsors conclude that just as DEHP is no longer legally allowed in make-up and personal care products, toys and other children's products sold in California, it is time for DEHP to be eliminated from these medical devices.
ASSEMBLY FLOOR: 58-1, 5/22/24
AYES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Juan Carrillo, Wendy Carrillo, Connolly, Mike Fong, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NOES: Dixon
NO VOTE RECORDED: Calderon, Cervantes, Chen, Megan Dahle, Davies, Essayli, Flora, Vince Fong, Friedman, Gallagher, Holden, Hoover, Lackey, Mathis, Jim Patterson, Joe Patterson, Luz Rivas, Sanchez, Ta, Waldron, Wallis
Prepared by: Melanie Moreno / HEALTH / (916) 651-4111
7/31/24 15:30:45
**** END ****
SENATE COMMITTEE ON ENVIRONMENTAL QUALITY
Senator Allen, Chair
2023 - 2024 Regular
Bill No. | AB 2300 | Hearing Date: | 7/3/2024 |
Author: | Wilson | ||
Version: | 6/27/2024 | ||
Urgency: | No | Fiscal: | No |
Consultant: | Gabrielle Meindl | ||
SUBJECT: Medical devices: Di-(2-ethylhexyl) phthalate (DEHP)
DIGEST: Prohibits the manufacture, sale, or distribution of intravenous solution containers and tubing made with intentionally added Di-(2-ethylhexyl) phthalate, as specified.
ANALYSIS:
Existing law:
- Establishes the Sherman Food, Drug, and Cosmetic Law (Sherman Law), administered by the California Department of Public Health (CDPH), which regulates the manufacture, packaging, labeling, and advertising of food, drugs, medical devices, and cosmetics. (HSC § 111929.4)
- Prohibits, commencing January 1, 2025, a person or entity from manufacturing, selling, delivering, holding, or offering for sale, in commerce any cosmetic product that contains, among other intentionally added ingredients, dibutyl phthalate (DBP) (CAS no. 84-74-2) and diethylhexyl phthalate (DEHP). (CAS no. 117-81-7) (HSC § 108980)
- Prohibits, commencing January 1, 2009, a person or entity from manufacturing, selling, or distributing in commerce any toy or child care article that contains di-(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate (DBP), or benzyl butyl phthalate (BBP), in concentrations exceeding 0.1%. (HSC § 108937 (a))
Under the California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65):
- Prohibits, a person, in the course of doing business, from knowingly and intentionally exposing any individual to a chemical known to the state to cause cancer or reproductive toxicity without first giving clear and reasonable warning to such individual. (HSC § 25249.6)
- Requires the Governor, on or before March 1, 1987, to publish a list of chemicals known to the state to cause cancer or reproductive toxicity and to revise and republish in light of additional knowledge at least once per year thereafter. The Office of Environmental Health Hazard Assessment (OEHHA) listed DEHP as a chemical known to the state to cause cancer on January 1, 1988, and as a chemical known to the state to cause reproductive toxicity (male reproductive toxicity and developmental toxicity). (HSC § 25249.8)
Under the Safer Consumer Products (Green Chemistry) statutes:
- Requires the Department of Toxic Substances Control (DTSC) to adopt regulations to establish a process to identify and prioritize chemicals or chemical ingredients in consumer products that may be considered chemicals of concern, as specified. (HSC § 25252)
- Requires DTSC to adopt regulations to establish a process to evaluate chemicals of concern in consumer products, and their potential alternatives, to determine how to best limit exposure or to reduce the level of hazard posed by a chemical of concern. (HSC § 25253 (a))
- Specifies, but does not limit, regulatory responses that DTSC can take following the completion of an alternatives analysis, ranging from no action to a prohibition of the chemical in the product. (HSC § 25253)
This bill:
- Defines "intentionally added DEHP" as DEHP that a manufacturer has intentionally added to an intravenous solution container or intravenous tubing product that has a functional or technical effect on the product.
- Defines "intravenous solution containers" as a container used to house medicine, fluid, or nutrition therapy that is intravenously administered to patients in a hospital, outpatient, or other health care facility.
- Defines "intravenous tubing" as any tubing used to intravenously administer fluids, medication, or nutrients directly to an adult, child, or infant.
- Defines "ortho-phthalates" as a class of chemicals that are esters of ortho-phthalic acid, as specified.
- Defines “unintentionally added DEHP” as DEHP in an intravenous solution container or intravenous tubing product that is not used for functional or technical effect on the product.
- Prohibits, commencing January 1, 2030, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
- Extends the above deadline to January 1, 2032, for a person or entity who has a pending United States Food and Drug Administration approval or who does not have adequate equipment to manufacture the DEHP-free intravenous solution container and who meets other specified requirements, including providing prescribed notices to consumers.
- Prohibits, commencing January 1, 2035, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous tubing made with intentionally added DEHP.
- Prohibits a person or entity from replacing DEHP, pursuant to the provisions of this bill, for revised or new products with other ortho-phthalates.
- Prohibits an intravenous solution container or intravenous tubing product having unintentionally added DEHP present at a quantity at or above 0.1 percent weight per weight (w/w).
- Exempts from the provisions of the bill human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing.
- Makes several legislative findings including that DEHP and other ortho-phthalates are toxic chemicals and can have negative impacts on human health as determined by the United States Food and Drug Administration, the United States Environmental Protection Agency, or the Office of Environmental Health Hazard Assessment within the California Environmental Protection Agency.
Background
- Proposition 65. Proposition 65, officially known as the Safe and Drinking Water and Toxic Enforcement Act of 1986, was enacted as a ballot initiative in November 1986. The proposition requires the state to maintain and update a list of chemicals known to the state to cause cancer or reproductive toxicity, protects the state's drinking water sources from being contaminated with chemicals known to cause cancer, birth defects, and other reproductive harm, and requires businesses to inform Californians about exposure to such chemicals. OEHHA is the lead agency for implementation of Proposition 65 and has the authority to adopt and modify regulations as necessary. According to OEEHA, the Proposition 65 list contains a wide range of naturally occurring and synthetic chemicals including additives or ingredients in pesticides, common household products, food, drugs, dyes, or solvents. The list was last updated on December 29, 2023, and contains DEHP, and other ortho-phthalates (BBP, DIDP, DBP, DnHP, and DINP).
- Sherman Food, Drug, and Cosmetic Law (Sherman Law). The Sherman law, administered by CDPH, ensures that food, drugs, and medical devices are safe and not adulterated, misbranded, or falsely advertised and that drugs and medical devices are effective. CDPH analyzes food, drugs, cosmetics, and other consumer products for chemical adulterations. Common analytes include toxic metals, seafood toxins, carcinogens, prescription drug ingredients, food additives, and preservatives.
- Phthalate use and exposure. The Centers for Disease Control and Prevention (CDC) describe phthalates as a group of chemicals used in hundreds of products ranging from personal care products to vinyl flooring. These synthetic chemicals have a wide range of uses and are a component of many products humans use on a day-to-day basis. Phthalates are often called plasticizers because they are used to make plastics more flexible and resistant to breaking. In industry, phthalates are commonly added to polyvinyl chloride (PVC) plastics. Phthalates are used in perfumes, nail polish, lubricants, medical tubing, blood bags, food and drink containers, and insect repellants: human exposure to phthalates is virtually unavoidable.
- Di-(2-ethylhexyl) phthalate (DEHP). DEHP was the first phthalate introduced as a plasticizer of PVC over nine decades ago. An article, published in Additives for Polymers in 2017, estimated the global consumption of DEHP at 3.07 million tons the previous year. DEHP has been listed in OEHHA's Proposition 65 list as causing cancer since 1988 and as a developmental and male reproductive toxicant since 2003. In 1988, the United States Environmental Protection Agency (US EPA) listed DEHP as a probable carcinogen. The listing was based on studies in mice and rats of both sexes that showed increased incidence of liver tumors. Decades after the listing of DEHP, it continues to be used in products found in our homes, work and healthcare facilities.
Proponents of AB 2300 highlighted published research articles that focus on DEHP and cancer. These studies among other things, describe; cell mechanisms (molecular pathways) linking DEHP to drug resistance in colorectal cancer and cell mechanisms by which DEHP is linked to drug resistance in triple-negative breast cancer (a cancer type that tends to grow and spread faster and has less treatment options). These findings have been published within the last four years and warrant additional studies to fully capture the impact of DEHP on cancer patients.
- Phthalates and healthcare. Phthalates are present in several types of medical devices including blood bags, tubing, catheters, and disposable gloves. The level of care and length of care patients receive determines how much exposure they will have to phthalates in this setting. DEHP is present in blood bags and other intravenous solution containers and intravenous tubing.
DEHP-free products have been readily available for some time now. In 2012, an article published in The Washington Post titled "Kaiser Permanente to use safer IV equipment," reports that Kaiser Permanente (Kaiser) had made a decision to buy IV solution bags that are 100% free of PVC and DEHP. The article further reports that in 2010, Kaiser was "the first of the industry to announce that it would require suppliers to provide environmental data for $1 billion worth of medical equipment and products used in Kaiser's hospitals, medical offices and other facilities." Access to their website confirms they were able to successfully phase out DEHP-containing IV solution bags. It is unclear how many other healthcare systems in California have implemented or started to implement similar changes.
- Actions by other countries. In 2018, the European Union (EU) amended its phthalates list to include DEHP. This meant that DEHP was added to their REACH (Registration, Evaluation, Authorization and Restriction of Chemical) Authorization list. As a result of the listing on REACH list, DEHP would be phased out of medical devices. In November 2023, an extension was granted to phase out DEHP. The new regulation states DEHP cannot be used in medical devices starting July 1, 2030, unless they apply for authorization before January 1, 2029. Authorization applications will be evaluated before approval.
- Alternatives in the market. According to information provided from the author's office, there are four major manufacturers of IV bags in the US that already supply DEHP-free intravenous solution containers or IV sets: B. Braun Medical, Fresenius Kabi, Baxter, and ICU Medical. Three of these companies have announced in recent years the expansion of their DEHP-free products, United States Food and Drug Administration (FDA) approval on their DEHP-free products or a new manufacturing center in the United States.
- Protecting Californians: The State Legislature has addressed the use of phthalates in several products. Assembly Bill (AB) 1108 (Ma, Chapter 11, Statutes of 2007) was signed into law to protect children from phthalate exposure. The list of phthalates included DEHP. AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) was signed into law to prevent DEHP and DBP, among other specified chemicals, from being intentionally added to cosmetic products. Policies prohibiting intentional use of other chemicals or disclosure of chemicals used have also been implemented demonstrating increased awareness of the chemicals used in many of the products Californians use or consume.
Comments
- Purpose of Bill. According to the author, “As a recent patient of the medical care system, I have first-hand knowledge related to the need for multiple infusions, with long durations, through medicines administered from IV bags. Each time you are potentially being exposed to a toxic material simply because we haven’t passed a law to ban this toxic material. There are alternatives, they are currently being used, and they aren’t more expensive. The State decided to ban the use of DEHP in kids' toys and cosmetics, I think it is time to ban this from medical containers that allow leaching directly into our bodies- when we are most vulnerable. People should be focused on their healthcare, not whether the very life-saving procedure is exposing them to cancer and other terrible health impacts.”
- Recent Senate Health Committee amendments address industry stakeholder concerns. According to a coalition letter from industry stakeholders, changing or substituting product materials is a highly complex process and subject to lengthy regulatory and testing requirements, and replacing the material for a single product can take years of extensive validation, biocompatibility, and performance testing. “AB 2300 will impact hundreds of product codes, and millions of intravenous bags and tubes used daily in the California market.” Given the robust manufacturing and FDA approval processes, industry stakeholders argue a longer timeline for compliance is needed to ensure a phased-in approach that prevents any disruption to the supply chain and patient care.
Amendments taken in Senate Health Committee on June 26, 2024, address this concern by extending the compliance timeline for intravenous solution containers by two years under certain circumstances: a person or entity has a pending FDA approval or does not have adequate equipment to manufacture the DEHP-free intravenous solution containers. The amendments further stipulate such persons or entities meet other specified requirements, including providing prescribed notices to consumers.
DOUBLE REFERRAL:
This measure was heard in Senate Health Committee on June 26, 2024, and passed out of committee with a vote of 11-0.
Related/Prior Legislation
AB 2244 (Ting, 2024) would prohibit, beginning on January 1, 2025, a paper proof of purchase (receipt), provided to a consumer by a business or created by a manufacturer, from containing bisphenol A (BPA) and would prohibit, beginning January 1, 2026, a paper proof of purchase, provided to a consumer by a business or created by a manufacturer, from containing any bisphenols. This bill is pending action in the Senate Appropriations Committee.
AB 418 (Gabriel, Chapter 17, Statutes of 2023) prohibits, beginning January 1, 2027, a person or entity from manufacturing, selling, delivering, distributing, holding, or offering for sale, in commerce a food product for human consumption that contains any of the following: brominated vegetable oil, potassium bromate, propylparaben, and red dye 3.
AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) prohibits, beginning January 1, 2025, prohibit a person or entity from manufacturing, selling, delivering, holding, or offering for sale, in commerce any cosmetic product that contains specified intentionally added ingredients. The list includes two phthalates: dibutyl phthalate (DBP, CAS no. 84-74-2) and diethylhexyl phthalate (DEHP, CAS no. 117-81-7).
SOURCE:
Breast Cancer Prevention Partners
SUPPORT:
A Voice for Choice Advocacy
Access Reproductive Justice
Alliance of Nurses for Healthy Environments
American College of Obstetricians and Gynecologists District Ix
Asian Americans Advancing Justice Southern California
Association of Regional Center Agencies
B. Braun Medical, INC.
Breast Cancer Prevention Partners
Buen Vecino
California Black Health Network
California Health Coalition Advocacy
California Nurses for Environmental Health and Justice
California Pan-ethnic Health Network
Calpirg, California Public Interest Research Group
Center for Community Action and Environmental Justice
Center for Environmental Health
Clean Production Action
Clean Water Action
Cleanearth4kids.org
Courage California
Defend Our Health
Educate. Advocate.
Fresenius Kabi
Health Care Without Harm
Health Equity for African American's League (HEAAL)
Healthy Contra Costa
Keep a Breast
Latino Coalition for A Healthy California
Made Safe
Mixteco Indigena Community Organizing Project
National Association of Environmental Medicine (NAEM)
National Stewardship Action Council
National Union of Healthcare Workers
Northern California Center for Well-being
Plastic Pollution Coalition
Prc/black Leadership Council
Public Health Advocates
San Francisco Bay Physicians for Social Responsibility
Science and Environmental Health Network
The Last Beach Cleanup
Urban Strategies Council
We ACT For Environmental Justice
Western Center on Law & Poverty, INC.
Women's Voices for The Earth
Young Invincibles
OPPOSITION:
None received
Positions reflect letters received by noon one week prior to the hearing.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Richard Roth, Chair
BILL NO: AB 2300
AUTHOR: | Wilson | ||
VERSION: | May 20, 2024 | ||
HEARING DATE: | June 26, 2024 | ||
CONSULTANT: | Melanie Moreno | ||
SUBJECT: Medical devices: Di-(2-ethylhexyl) phthalate (DEHP)
SUMMARY:
- Prohibits the manufacture, sale, or distribution of intravenous solution containers and tubing made with intentionally added Di-(2-ethylhexyl) phthalate.
Existing law:
- Prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or childcare article that contains, among other things, Di-(2-ethylhexyl) phthalate (DEHP) in concentrations exceeding 0.1%. Prohibits manufacturers from replacing phthalates in these products with specified carcinogens, or substances listed as known or likely carcinogens, known to be human carcinogens, likely to be human carcinogens, or suggestive of being human carcinogens, or reproductive toxicants that cause birth defects, reproductive harm, or developmental harm. [HSC §108937 and §108939]
- Prohibits, commencing January 1, 2025, a person or entity from manufacturing any cosmetic that contains intentionally added DEHP. [HSC §108980]
This bill:
- Prohibits the manufacture, sale, or distribution of intravenous solution containers made with intentionally added DEHP beginning January 1, 2030 and of intravenous tubing made with intentionally added DEHP beginning January 1, 2035.
- Prohibits the replacement of DEHP in these products, for revised or new products, with other ortho-phthalates.
- Prohibits an intravenous solution container or intravenous tubing product from having unintentionally added DEHP present at a quantity at or above 0.1%.
- Exempts human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing, from the prohibitions contained in this bill.
FISCAL EFFECT:
This bill is keyed non-fiscal.
PRIOR VOTES:
Assembly Floor: | 58 - 1 |
Assembly ESTM Committee | 5 - 1 |
Assembly Health Committee: | 10 - 1 |
COMMENTS:
- Author’s statement. According to the author, as a recent patient of the medical care system, I have first-hand knowledge related to the need for multiple infusions, with long durations, through medicines administered from IV bags. Each time, you are potentially being exposed to a toxic material simply because we haven’t passed a law to ban this toxic material. There are alternatives; they are currently being used and aren’t more expensive. The State decided to ban the use of DEHP in kids' toys and cosmetics; I think it is time to ban this from medical containers that allow leaching directly into our bodies- when we are most vulnerable. People should be focused on their healthcare, not whether the very life-saving procedure is exposing them to cancer and other terrible health impacts.
- Background. DEHP belongs to a family of chemicals called phthalates, and is widely considered to have toxic effects: the U.S. Department of Health and Human Services classified DEHP as reasonably anticipated to be a human carcinogen; the U.S. Environmental Protection Agency has determined that DEHP is a probable human carcinogen; and, the International Agency for Research on Cancer has classified DEHP as possibly carcinogenic to humans. In September 2002, the federal Agency for Toxics Substances and Disease Registry issued a Public Health Statement regarding DEHP because it was considered to be a hazardous substance. According to the statement, DEHP is a colorless liquid with almost no odor that is commonly added to plastics to make them flexible. DEHP does not evaporate easily, and little will be present in the air even near sources of production. It is used in many products that are made from plastic, but especially in polyvinyl chloride (PVC) or vinyl. DEHP is on California’s Proposition 65 list because it can cause cancer and birth defects or other reproductive harm. According to the Proposition 65 Warnings Website, in the past, DEHP was one of the phthalates most frequently used in plastic products, but its use has decreased in recent years. DEHP is still used in various types of plastic consumer products, including: shower curtains, furniture and automobile upholstery, garden hoses, floor tiles, coverings on wires and cables, rainwear, shoes, lunchboxes, binders, and backpacks, plastic food packaging materials, medical devices and equipment (including some types of blood and intravenous solution bags, tubing for dialysis, feeding tubes, oxygen masks, and surgical gloves). California law prohibits the manufacture, sale, or distribution of children’s toys and childcare articles containing DEHP at levels greater than 0.1%. Federal law has a similar prohibition.
- DEHP in medical devices. According to a 2015 review published in the Transfusion Medicine Reviews Journal, PVC is used in many medical devices because it shows optimal inertness, durability, and resistance to heat and chemicals. However, PVC needs to be plasticized, and DEHP has been the most common plasticizer to produce flexibility. DEHP has been found to leach out from the containers and devices, causing toxic effects, demonstrated mainly in rodents. In September 2002, the FDA issued a Guidance for Industry recommending that manufacturers label medical devices made with DEHP and manufacturers consider replacing PVC containing DEHP with alternative materials, stating that devices used in Neonatal Intensive Care Units (NICUs) should be a primary focus. A December 2012 Guidance for Industry states that because the FDA determined that there is evidence that exposure to DEHP from pharmaceuticals presents a potential risk of developmental and reproductive toxicity, and safer alternatives are available, the FDA recommends the use of DEHP be avoided as excipients in regulated drug and biologic products. The first study to document the amount of phthalates leached from various medical supplies and associated exposures was published in May 2023. The study found that DEHP was the major phthalate found in 99% of the samples analyzed, with the highest amount leached from respiratory support devices. DEHP was also found at notable concentrations in products labeled as “DEHP-free.” However, the amounts of DEHP leached from those products were lower than those of other medical devices. Direct exposure to phthalates from the use of medical devices and first aid supplies and dermal intake from the use of creams/lotions were also calculated. The highest DEHP exposure dose was determined from the use of cannula for neonates. The study authors concluded by stating that efforts should be made to regulate phthalates in medical devices, and the safety of other alternative plasticizers that are currently used as replacements should be examined. The chemical safety of medical devices is of vital importance to help safeguard the health of patients, especially newborns, and efforts are needed to address the critical issue urgently.
- Double referral. This bill has been double referred. Should it pass out of this Committee, it will be referred to the Committee on Environmental Quality.
- Related legislation. AB 347 (Ting) Permits the Department of Toxic Substances Control (DTSC) to regulate and enforce compliance of existing per- and poly-fluoroalkyl substances (PFAS) restrictions in juvenile products, textile articles, cosmetics, plant-based food packaging, and noticing requirements for cookware. AB 347 requires manufacturers of these products to comply with a number of actions regarding the registration and testing of the products, and requires DTSC to submit a report to the Legislature regarding its compliance and enforcement activities. AB 347 is set to be heard in this Committee on July 3, 2024.
- Prior legislation. AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) prohibits, beginning January 1, 2025, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing specified intentionally added ingredients, including DEHP.
AB 1108 (Ma, Chapter 672, Statutes of 2008) prohibits the use of DEHP and other phthalates in toys and childcare products.
- Support. Breast Cancer Prevention Partners, California Black Health Network, and the American College of Obstetricians and Gynecologists (cosponsors of this bill) state that research indicates that DEHP promotes drug resistance and inhibits the effectiveness of breast cancer drugs; interferes with the ability of chemotherapies to fight breast cancer, and that patients with higher levels of DEHP in their system had higher rates of relapse and mortality. California's standards for medical devices needs to be higher. DEHP is harmful throughout its entire life cycle, from manufacturing to disposal, and it has serious impacts that extend beyond human health. Non-DEHP containers and tubing have been available for decades. The cosponsors conclude that just as DEHP is no longer legally allowed in make-up and personal care products, toys and other children's products sold in California, it is time for DEHP to be eliminated from these medical devices
- Oppose unless amended. Opponents write that changing or substituting product materials is a highly complex process and subject to lengthy regulatory and testing requirements, and replacing the material for a single product can take years of extensive validation, biocompatibility, and performance testing. This bill will impact hundreds of product codes, and millions of intravenous bags and tubes used daily in the California market. Given the robust manufacturing and FDA approval processes, the opposition coalition believes a longer timeline for compliance is needed to ensure a phased-in approach that prevents any disruption to the supply chain and patient care. While many companies have started the transition to DEHP-free products, enabling several product configurations to become available as early as 2027, they continue to believe a later implementation date is needed for a successful transition. The opposition writes that a 2035 implementation date is appropriate for the bill. However, recognizing the author’s desire for the state to move faster, their organizations have worked diligently over the past month to figure out solutions to speed up the process. With adjustments to additional validation studies, and reducing product enhancements, opponents believe the timeline can be reduced by two years. They ask that this bill be amended to make the effective date of 2033 for intravenous solution containers.
SUPPORT AND OPPOSITION:
Support: American College of Obstetricians and Gynecologists District IX (co-sponsor)
Breast Cancer Prevention Partners (co-sponsor)
California Black Health Network (co-sponsor)
A Voice for Choice Advocacy
Access Reproductive Justice
Alliance of Nurses for Healthy Environments
Asian Americans Advancing Justice Southern California
Association of Regional Center Agencies
B. Braun Medical, Inc.
Buen Vecino
California Health Coalition Advocacy
California Nurses for Environmental Health and Justice
California Pan-Ethnic Health Network
California Public Interest Research Group
Center for Community Action and Environmental Justice
Center for Environmental Health
Clean Production Action
Clean Water Action
Cleanearth4kids.org
Courage California
Defend Our Health
Educate. Advocate.
Fresenius Kabi
Health Care Without Harm
Health Equity for African American’s League
Healthy Contra Costa
Keep a Breast
Latino Coalition for a Healthy California
Made Safe
Mixteco Indigena Community Organizing Project
National Association of Environmental Medicine
National Stewardship of Action Council
National Union of Healthcare Workers
Northern California Center for Well-Being
Plastic Pollution Coalition
PRC & Black Leadership Council
Public Health Advocates
San Francisco Bay Physicians for Social Responsibility
Science and Environmental Health Network
Sharp Healthcare
The Last Beach Cleanup
Urban Strategies Council
Western Center on Law & Poverty, Inc.
Women’s Voices for the Earth
Young Invincibles
Oppose: Advanced Medical Technology Association (unless amended)
American Chemistry Council (unless amended)
Baxter Healthcare (unless amended)
Biocom California (unless amended)
California Life Sciences (unless amended)
California Manufactures & Technology Association (unless amended)
Flexible Vinyl Alliance (unless amended)
Vinyl Institute (unless amended)
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 2300
Author:(Wilson)
As Amended Ver:May 20, 2024
Majority vote
SUMMARY
Prohibits, beginning January 1, 2030, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution (IV) containers made with intentionally added di-(2-ethylhexyl) phthalate (DEHP). Additionally prohibits, beginning January 1, 2035, a person or entity from manufacturing, selling or distributing into commerce IV tubing made with intentionally added DEHP. Prohibits an intravenous solution container or intravenous tubing product from having unintentionally added DEHP present at a quantity at or above 0.1%. Exempts from the provisions of this bill human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing.
Major Provisions
COMMENTS
DEHP. DEHP belongs to a family of chemicals called phthalates, which are added to some plastics to make them flexible. An article, published in Additives for Polymers in 2017, estimated the global consumption of DEHP at 3.07 million tons the previous year. DEHP has been listed on the California Office of Health Hazard Assessment (OEHHA)'s Proposition 65 list as causing cancer since 1988 and a developmental and male reproductive toxicant since 2003. In 1988, the U.S. Environmental Protection Agency listed DEHP as a probable carcinogen.
DEHP and healthcare. DEHP is present in medical devices such as catheters, disposable gloves IV containers, IV tubing, and blood bags.
European Union (EU) ban. In 2018, the EU added DEHP to their REACH (Registration, Evaluation, Authorization and Restriction of Chemical) Authorization list. As a result of inclusion on the REACH list, DEHP is required to be phased out of medical devices. Per the EU's November 2023 regulation, DEHP cannot be used in medical devices starting July 1, 2030, unless manufacturers apply for authorization before January 1, 2029. Authorization applications will be evaluated before approval.
Alternatives in the market. At least four major manufactures of IV bags in the US already supply DEHP-free IV solution containers or IV sets: B. Braun Medical, Fresenius Kabi, Baxter, and ICU Medical. Kaiser reports on their website that they have successfully phased out IV solution bags that contain DEHP. It is unclear how many other healthcare systems in California have implemented or started to implement similar changes.
According to the Author
According to the author, "As a recent patient of the medical care system, I have first-hand knowledge related to the need for multiple infusions, with long durations, through medicines administered from IV bags. Each time you are potentially being exposed to a toxic material simply because we haven't passed a law to ban this toxic material. There are alternatives, they are currently being used, and they aren't more expensive. The State decided to ban the use of DEHP in kids' toys, I think it is time to ban this from medical containers that allow leaching directly into our bodies- when we are most vulnerable. People should be focused on their healthcare, not whether the very life-saving procedure is exposing them to cancer-causing chemicals and other terrible health impacts."
Arguments in Support
Breast Cancer Prevention Partners and California Black Health Network, cosponsors of this bill, state that research indicates that DEHP promotes drug resistance and inhibits the effectiveness of breast cancer drugs; interferes with the ability of chemotherapies to fight breast cancer, and that patients with higher levels of DEHP in their system had higher rates of relapse and mortality. California's standards for medical devices need to be higher. DEHP is harmful throughout its entire life cycle, from manufacturing to disposal, and it has serious impacts that extend beyond human health. Non-DEHP containers and tubing have been available for decades. The cosponsors conclude that just as DEHP is no longer legally allowed in make-up and personal care products, toys and other children's products sold in California, it is time for DEHP to be eliminated from these medical devices.
Arguments in Opposition
A coalition of industry stakeholders opposes this bill unless amended. The coalition states that medical devices and drugs are distributed nationally, and the US Food and Drug Administration (FDA) regulatory process provides manufacturers, healthcare providers, and patients with a consistent set of rules governing product safety. Changing or substituting product materials is a highly complex process and subject to strict regulatory requirements and lengthy approval times. To address concerns related to the manufacturing and the FDA approval process, the coalition requests that the bill be amended to delay the effective date of the requirements of the bill as it relates to IV tubing and solution containers to 2035. To allow manufacturers to test products to ensure compliance, the coalition requests that the definition of "intentionally added DEHP" be amended to include 0.1 weight per weight threshold.
FISCAL COMMENTS
None.
VOTES
ASM HEALTH: 10-1-5
YES: Bonta, Aguiar-Curry, Arambula, Wendy Carrillo, Haney, Maienschein, Rodriguez, Santiago, Schiavo, Weber
NO: Jones-Sawyer
ABS, ABST OR NV: Waldron, Flora, McCarty, Joe Patterson, Sanchez
ASM ENVIRONMENTAL SAFETY AND TOXIC MATERIALS: 5-1-1
YES: Garcia, Connolly, McKinnor, Papan, Reyes
NO: Hoover
ABS, ABST OR NV: Ta
UPDATED
VERSION: May 20, 2024
CONSULTANT: Eliza Brooks / HEALTH / (916) 319-2097 FN: 0003349
ASSEMBLY THIRD READING
ATR Bill Id:AB 2300
Author:(Wilson)
As Amended Ver:April 1, 2024
Majority vote
SUMMARY
Prohibits, beginning January 1, 2026, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution (IV) containers made with intentionally added di-(2-ethylhexyl) phthalate (DEHP). Additionally prohibits, beginning January 1, 2031, a person or entity from manufacturing, selling or distributing into commerce IV tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions. Exempts from the provisions of this bill human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing.
Major Provisions
COMMENTS
DEHP. DEHP belongs to a family of chemicals called phthalates, which are added to some plastics to make them flexible. An article, published in Additives for Polymers in 2017, estimated the global consumption of DEHP at 3.07 million tons the previous year. DEHP has been listed on the California Office of Health Hazard Assessment (OEHHA)'s Proposition 65 list as causing cancer since 1988 and a developmental and male reproductive toxicant since 2003. The evidence reviewed by OEHHA included research studies in small mammals (mice, rats, and hamsters). The findings were a decrease in testicular weight and testicular atrophy (decreased size) and reduced fertility. Studies also reported developmental toxicities when a metabolite of DEHP was given. In 1988, the U.S. Environmental Protection Agency listed DEHP as a probable carcinogen. The listing was based on studies in mice and rats of both sexes that showed increased incidence of liver tumors.
DEHP and healthcare. DEHP is present in medical devices such as catheters, disposable gloves, IV containers, IV tubing, and blood bags. The level of care and length of care patients receive determines how much exposure they will have to DEHP in this setting.
European Union (EU) ban. In 2018, the EU added DEHP to their REACH (Registration, Evaluation, Authorization, and Restriction of Chemical) Authorization list.
As a result of inclusion on the REACH list, DEHP is required to be phased out of medical devices. Per the EU's November 2023 regulation, DEHP cannot be used in medical devices starting July 1, 2030, unless manufacturers apply for authorization before January 1, 2029. Authorization applications will be evaluated before approval.
Alternatives in the market. At least four major manufactures of IV bags in the US already supply DEHP-free IV solution containers or IV sets: B. Braun Medical, Fresenius Kabi, Baxter, and ICU Medical. Kaiser reports on their website that they have successfully phased out IV solution bags that contain DEHP. It is unclear how many other healthcare systems in California have implemented or started to implement similar changes.
According to the Author
According to the author, "As a recent patient of the medical care system, I have first-hand knowledge related to the need for multiple infusions, with long durations, through medicines administered from IV bags. Each time you are potentially being exposed to a toxic material simply because we haven't passed a law to ban this toxic material. There are alternatives, they are currently being used, and they aren't more expensive. The State decided to ban the use of DEHP in kids' toys, I think it is time to ban this from medical containers that allow leaching directly into our bodies when we are most vulnerable. People should be focused on their healthcare, not whether the very life-saving procedure is exposing them to cancer-causing chemicals and other terrible health impacts."
Arguments in Support
Breast Cancer Prevention Partners and California Black Health Network, cosponsors of this bill, state that research indicates that DEHP promotes drug resistance and inhibits the effectiveness of breast cancer drugs; interferes with the ability of chemotherapies to fight breast cancer, and that patients with higher levels of DEHP in their system had higher rates of relapse and mortality. California's standards for medical devices need to be higher. DEHP is harmful throughout its entire life cycle, from manufacturing to disposal, and it has serious impacts that extend beyond human health. Non-DEHP containers and tubing have been available for decades. The cosponsors conclude that just as DEHP is no longer legally allowed in make-up and personal care products, toys and other children's products sold in California, it is time for DEHP to be eliminated from these medical devices.
Arguments in Opposition Unless Amended
A coalition of industry stakeholders opposes this bill unless amended. The coalition states that medical devices and drugs are distributed nationally, and the US Food and Drug Administration (FDA) regulatory process provides manufacturers, healthcare providers, and patients with a consistent set of rules governing product safety. Changing or substituting product materials is a highly complex process and subject to strict regulatory requirements and lengthy approval times. To address concerns related to the manufacturing and the FDA approval process, the coalition requests that the bill be amended to delay implementation of the requirements of the bill as it relates to IV tubing and solution containers. To allow manufacturers to test products to ensure compliance, the coalition requests that the definition of "intentionally added DEHP" be amended to include 0.1 weight per weight threshold.
FISCAL COMMENTS
None.
VOTES
ASM HEALTH: 10-1-5
YES: Bonta, Aguiar-Curry, Arambula, Wendy Carrillo, Haney, Maienschein, Rodriguez, Santiago, Schiavo, Weber
NO: Jones-Sawyer
ABS, ABST OR NV: Waldron, Flora, McCarty, Joe Patterson, Sanchez
ASM ENVIRONMENTAL SAFETY AND TOXIC MATERIALS: 5-1-1
YES: Garcia, Connolly, McKinnor, Papan, Reyes
NO: Hoover
ABS, ABST OR NV: Ta
UPDATED
VERSION: April 1, 2024
CONSULTANT: Eliza Brooks / HEALTH / (916) 319-2097 FN: 0002785
Date of Hearing: April 23, 2024
ASSEMBLY COMMITTEE ON ENVIRONMENTAL SAFETY AND TOXIC MATERIALS
Eduardo Garcia, Chair
ABPCA Bill Id:AB 2300 (
Author:Wilson) – As Amended Ver:April 1, 2024
SUBJECT: Medical devices: Di-(2-ethylhexyl) phthalate (DEHP)
SUMMARY: Prohibits, beginning January 1, 2026, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution containers made with intentionally added DEHP; prohibits, beginning January 1, 2031, a person or entity from manufacturing, selling or distributing into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions; prohibits a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates; and, exempts, from the prohibition of using DEHP, human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing. Specifically, this bill:
- Defines "DEHP" as Di(2-ethylhexyl) phthalate.
- Defines "intentionally added DEHP" as DEHP that a manufacturer has intentionally added to a product and that has functional or technical effect on the product.
- Defines "intravenous solution containers" as a container used to house medicine, fluid, or nutrition therapy that is intravenously administered to patients in a hospital, outpatient, or other health care facility.
- Defines "intravenous tubing" as any tubing used to administer fluids, medication, or nutrient directly to an adult, child, or infant.
- Defines "ortho-phthalates" as a class of chemicals that are esters of ortho-phthalic acid, including all of the following:
- Benzyl-butyl phthalate (BBP) 85-68-7.
- Dibutyl phthalate (DBP) 84-74-2.
- Dicyclohexyl phthalate (DCHP) 84-61-7.
- Di-(2-ethylhexyl) phthalate (DEHP) 117-81-7.
- Diethyl phthalate (DEP) 84-66-2.
- Di-isobutyl phthalate (DIBP) 84-69-5.
- Di-isodecyl phthalate (DIDP) 26761-40-0.
- Di-isononyl phthalate (DINP) 28553-12-0.
- Di-n-hexyl phthalate (DnHP) 84-75-3.
- Di-n-octyl phthalate (DNOP) 117-84-0.
- Di-n-pentyl (DnPP) phthalate 131-18-0.
- Diisoheptyl phthalate (DIHP) 71888-89-6.
- Prohibits commencing January 1, 2026, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
- Prohibits, commencing January 1, 2031, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions.
- Prohibits a person or entity from replacing DEHP, pursuant to the provisions of this bill, for revised or new products with other ortho-phthalates.
- Exempts from the provisions of the bill human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing.
- Makes several legislative findings stating: that DEHP and other ortho-phthalates are toxic chemicals; ortho-phthalates produce flexibility in plastics; DEHP is the most commonly used 'plasticizer' in medical devices, including intravenous (IV) solution containers and intravenous tubing; DEHP leaches out of the plastic into the solution being held in the container; DEHP is classified as an endocrine (hormone)-disrupting compound affecting reproductive health, development, and metabolism; studies have suggested a potential link between DEHP exposure and certain types of cancer (e.g. breast, liver, lung, and testicular cancer); the United States Environmental Protection Agency (US EPA) has determined that DEHP is a probable human carcinogen, and it is listed on the Proposition 65 list; DEHP is metabolized in the liver and can accumulate in the body over time; prolonged exposure to high levels of DEHP has been shown to cause liver and kidney damage in animal studies; inhalation or ingestion of DEHP can cause respiratory irritation and allergic reaction particularly those with preexisting respiratory conditions or sensitivities; approximately 70 percent of California hospitals are buying and using toxic IV bags exposing patients directly to DEHP; exposure to DEHP has been linked to multidrug resistance in triple-negative breast cancer cells, inhibiting the apoptosis mechanism induced by breast cancer drugs such as tamoxifen and increasing cell proliferation; and, DEHP has been suggested to serve as a mitogenic factor for estrogen receptor-positive breast cancer cells, potentially making them multidrug resistant.
EXISTING LAW:
- Defines "person" as any person, firm, association, organization, partnership, business trust, corporation, limited liability company, or company. (Health and Safety Code (HSC) § 19)
- Establishes the Sherman Food, Drug, and Cosmetic Law (Sherman Law), administered by the California Department of Public Health (CDPH), which regulates the manufacture, packaging, labeling, and advertising of food, drugs, medical devices, and cosmetics. (HSC § 111929.4)
- Prohibits, commencing January 1, 2025, a person or entity from manufacturing, selling, delivering, holding, or offering for sale, in commerce any cosmetic product that contains, among other intentionally added ingredients, dibutyl phthalate (DBP) (CAS no. 84-74-2) and diethylhexyl phthalate (DEHP). (CAS no. 117-81-7) (HSC § 108980)
- Prohibits, commencing January 1, 2009, a person or entity from manufacturing, selling, or distributing in commerce any toy or child care article that contains di-(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate (DBP), or benzyl butyl phthalate (BBP), in concentrations exceeding 0.1%. (HSC § 108937 (a))
- Prohibits, commencing January 1, 2009, a person or entity from manufacturing, selling, or distributing in commerce any toy or child care article intended for use by a child under three years of age if that product can be placed in the child's mouth and contains diisononyl phthalate (DINP), diisodecyl phthalate (DIDP), or di-n-octyl phthalate (DnOP), in concentrations exceeding 0.1 percent. (HSC § 108937 (b))
Under the California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65):
- Prohibits, a person, in the course of doing business, from knowingly and intentionally exposing any individual to a chemical known to the state to cause cancer or reproductive toxicity without first giving clear and reasonable warning to such individual. (HSC § 25249.6)
- Requires the Governor, on or before March 1, 1987, to publish a list of chemicals known to the state to cause cancer or reproductive toxicity and to revise and republish in light of additional knowledge at least once per year thereafter. The Office of Environmental Health Hazard Assessment (OEHHA) listed DEHP as a chemical known to the state to cause cancer on January, 1, 1988 and as a chemical known to the state to cause reproductive toxicity (male reproductive toxicity and developmental toxicity). (HSC § 25249.8)
Under the Safer Consumer Products (Green Chemistry) statutes:
- Requires DTSC to adopt regulations to establish a process to identify and prioritize chemicals or chemical ingredients in consumer products that may be considered chemicals of concern, as specified. (HSC § 25252)
- Requires DTSC to adopt regulations to establish a process to evaluate chemicals of concern in consumer products, and their potential alternatives, to determine how to best limit exposure or to reduce the level of hazard posed by a chemical of concern. (HSC § 25253 (a))
- Specifies, but does not limit, regulatory responses that DTSC can take following the completion of an alternatives analysis, ranging from no action, to a prohibition of the chemical in the product. (HSC § 25253)
FISCAL EFFECT: Unknown
COMMENTS:
Need for the bill: According to the author:
"As a recent patient of the medical care system, I have first-hand knowledge related to the need for multiple infusions, with long durations, through medicines administered from IV bags. Each time you are potentially being exposed to a toxic material simply because we haven’t passed a law to ban this toxic material. There are alternatives, they are currently being used, and they aren’t more expensive. The State decided to ban the use of DEHP in kid's toys, I think it is time to ban this from medical containers that allow leaching directly into our bodies- when we are most vulnerable. People should be focused on their healthcare, not whether the very life-saving procedure is exposing them to cancer and other terrible health impacts."
Proposition 65: Proposition 65, officially known as the Safe and Drinking Water and Toxic Enforcement Act of 1986, was enacted as a ballot initiative in November 1986. The proposition requires the state to maintain and update a list of chemicals known to the state to cause cancer or reproductive toxicity, protects the state's drinking water sources from being contaminated with chemicals known to cause cancer, birth defects and other reproductive harm and requires businesses to inform Californians about exposure to such chemicals. OEHHA is the lead agency for implementation of Proposition 65 and has the authority to adopt and modify regulations as necessary. According to OEEHA, the proposition 65 list contains a wide range of naturally occurring and synthetic chemicals including additives or ingredients in pesticides, common household products, food, drugs, dyes, or solvents. The list was last updated on December 29, 2023 and contains DEHP, and other ortho-phthalates (BBP, DIDP, DBP, DnHP, and DINP).
Sherman Food, Drug, and Cosmetic Law (Sherman Law): The Sherman law, administered by CDPH, ensures that food, drugs, and medical devices are safe and not adulterated, misbranded or falsely advertised, and that drugs and medical devices are effective. CDPH analyzes food, drugs, cosmetics, and other consumer products for chemical adulterations. Common analytes include toxic metals, seafood toxins, carcinogens, prescription drug ingredients, food additives and preservatives.
Phthalate use and exposure: The Centers for Disease Control and Prevention (CDC) describe phthalates as a group of chemicals used in hundreds of products ranging from personal care products to vinyl flooring. These synthetics chemicals have a wide range of uses and are a component of many products humans use on a day to day basis. Phthalates are often called plasticizers because they are used to make plastics more flexible and resistant to breaking. In industry, phthalates are commonly added to polyvinyl chloride (PVC) plastics. Phthalates are used in perfumes, nail polish, lubricants, medical tubing, blood bags, food and drink containers, and insect repellants: human exposure to phthalates is virtually unavoidable.
Di-(2-ethylhexyl) phthalate (DEHP): DEHP was the first phthalate introduced as a plasticizer of PVC over nine decades ago. An article, published in Additives for Polymers in 2017, estimated the global consumption of DEHP at 3.07 million tons the previous year. DEHP has been listed in OEHHA's Proposition 65 list as causing cancer since 1988 and a developmental and male reproductive toxicant since 2003. In 1988, the US EPA listed DEHP as a probable carcinogen. The listing was based on studies in mice and rats of both sexes that showed increased incidence of liver tumors.
Prior to listing a chemical under Prop 65, OEHHA scientists review peer-reviewed research articles. The evidence reviewed by OEHHA included research studies in small mammals (mice, rats, and hamsters). The findings were a decrease in testicular weight and testicular atrophy (decreased size) and reduced fertility. Additionally, studies that reported developmental toxicities, like skeletal abnormalities and exencephaly (brain outside the skull), after giving mice DEHP were also reported when mono-(2-ethylhexyl) (MEHP) a metabolite of DEHP (a product of the breakdown of DEHP) was given. The literature reviewed and appropriate conclusions can be found on OEHHA's website.
Decades after the listing of DEHP, we continue using DEHP in products found in our homes, work and healthcare facilities. The research on DEHP continue to advance increasing our understanding of health risks with DEHP exposure. In a review article published in Biomed Research International titled, "Toxic Effects of Di-2-Ethylhexyl Phthalate: An Overview," different research studies are summarized indicating DEHP is an endocrine disruptor interfering with hormone signaling in various organs. Small mammals that were exposed to DEHP before birth, had lower concentrations of reproductive hormone, like testosterone. Reduced steroidogenesis, the process by which cholesterol is converted to steroid hormones (e.g. testosterone, estrogen, cortisol) is also observed. DEHP created histopathological changes (changes in the tissue, cells or structure indicating signs of a disease) in the thyroid. Toxicity to the brain, liver and kidneys has also been observed.
Proponents of AB 2300 highlighted published research articles that focus on DEHP and cancer. These studies among other things, describe; cell mechanisms (molecular pathways) linking DEHP to drug resistance in colorectal cancer and cell mechanisms by which DEHP is linked to drug resistance in triple negative breast cancer (a cancer type that tends to grow and spread faster and has less treatment options). These findings have been published within the last four years and warrant additional studies to fully capture the impact of DEHP on cancer patients.
Phthalates and healthcare: Phthalates are present in several types of medical devices including blood bags, tubing, catheters, and disposable gloves. The level of care and length of care patients receive determines how much exposure they will have to phthalates in this setting. DEHP is present in blood bags and other intravenous solution containers and intravenous tubing.
DEHP-free products have been readily available for some time now. In 2012, an article published in The Washington Post titled "Kaiser Permanente to use safer IV equipment," reports that Kaiser Permanente (Kaiser) had made a decision to buy IV solution bags that are 100% free of PVC and DEHP. The article further reports that in 2010, Kaiser was "the first of the industry to announce that it would require suppliers to provide environmental data for $1 billion worth of medical equipment and products used in Kaiser's hospitals, medical offices and other facilities." Access to their website confirms they were able to successfully phase out DEHP containing IV solution bags. It is unclear how many other healthcare systems in California have implemented or started to implement similar changes.
Actions by other countries: In 2018, the European Union (EU) amended their phthalates list to include DEHP. This meant that DEHP was added to their REACH (Registration, Evaluation, Authorization and Restriction of Chemical) Authorization list. As a result of the listing on REACH list DEHP would be phased out of medical devices. On November 2023, an extension was granted to phase out DEHP. The new regulation states DEHP cannot be used in medical devices starting July 1, 2030, unless they apply for authorization before January 1, 2029. Authorization applications will be evaluated before approval.
Alternatives in the market: According to information provided from the author's office, there are four major manufactures of IV bags in the US that already supply DEHP-free intravenous solution containers or IV sets: B. Braun Medical, Fresenius Kabi, Baxter, and ICU Medical. Three of these companies have announced in recent years expansion of their DEHP-free products, FDA approval on their DEHP-free products or a new manufacturing center in the United States.
Protecting Californians: The State Legislature has addressed the use of phthalates in several products. Assembly Bill (AB) 1108 (Ma, Chapter 11, Statutes of 2007) was signed into law to protect children from phthalate exposure. The list of phthalates included DEHP. AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) was signed into law to prevent DEHP and DBP, among other specified chemicals, from being intentionally added to cosmetic products. Policies prohibiting intentional use of other chemicals or disclosure of chemicals used have also been implemented demonstrating increased awareness on the chemicals used in many of the products Californians use or consume. The provisions of this bill regarding intravenous tubing protect vulnerable groups: those in neonatal intensive care units, those receiving nutrition infusions, or those receiving oncology treatment infusions. People receiving care in these areas are already in a vulnerable state (e.g. immunocompromised, nutrient deficient) and because of this they disproportionally bear the burden of higher exposure compared to other patients.
The importance of supply: The provisions of this bill provide two timelines for removing DEHP from intravenous solution containers and intravenous tubing. Furthermore, they focus on reducing exposure of DEHP, through intravenous tubing, in neonatal intensive care units, nutrition infusions, or oncology treatment infusions. The implementation of DEHP-free intravenous tubing in these areas first can inform the timeline of future additional protections (if desired). Some proponents of the bill would like to expand coverage and concerns arise over the ability to cover that demand. As this bill moves through the legislative process, the author may wish to continue conversations with the industry to ensure supply shortages don't affect healthcare services and result in unintended consequences.
Blood Bags: While AB 2300 was in Assembly Health Committee it was amended to exempt blood bags and materials associated with blood collection. This amendment was critical for two reasons; research studies have demonstrated that DEHP bags are critical in preventing haemolysis- that is, preventing the destruction of red blood cells- and because despite several studies trying to identify an effective alternative to DEHP for blood storage, more research is needed. In a news article, published August 2023 titled, "Paving the Way for the Future of Blood Transfusions," the medical device manufacturer Fresenius Kabi presents their promising DEHP-free blood bag system and discusses the challenges and considerations in finding proper replacements. This news and numerous peer-reviewed research articles that have reported findings on possible alternatives demonstrate that scientists are committed to finding solutions, but they need more time. This amendment prevented a possible unintended consequence from happening: a blood supply shortage in California.
Enforcement: Existing law, the Sherman Food, Drug, and Cosmetic Law, enforced by CDPH covers medical devices. The provisions of this bill do not delegate authority for enforcement to any department. California has passed legislation, which ultimately became law, prohibiting the use of certain chemicals without delegating authority to any department. In other instances, legislation without an enforcing department has been sent to the Governor, but was vetoed. The European Union's regulation to remove DEHP from medical devices includes an option for applying for authorized use. The intent behind this provision is likely to allow, in unique circumstances, the use of DEHP if safe alternatives are not available. As this bill moves through the legislative process, the author is encouraged to continue conversations with stakeholders and CDPH to determine a framework for enforcement. Additionally, consideration may be given to an authorized use process similar to the European Union to address unforeseeable problems. This may also ease concerns about the current timeline in AB 2300.
Regrettable substitutes: Chemical bans require manufacturers to switch to alternatives. We have previously had situations where replacements for one chemical result in another with similar toxicity profiles. The perfect example of regrettable substitutions is BPA to BPS. The provisions of this bill include a list of phthalates that are not permitted as substitutes. As this bill moves through the legislative process, the author may wish to consider including language to prohibit manufactures from using other harmful (reproductive toxicants or carcinogenic) chemicals.
Intentionally added DEHP vs trace amount: Many pieces of legislations over the years have focused on prohibiting toxic chemicals in cosmetics, food ware and other items. This bill clearly defines "intentionally added DEHP." However, it does not provided language to account for trace amounts that may be found in products. Due to the widespread and long term use of DEHP, the author may wish to consider adding language to include a threshold amount or account for trace amounts. This would address the concerns raised by the opposition.
Legislative findings: As this bills moves through the process, the author is encouraged to review the legislative findings, possibly consult OEHHA scientists, to ensure findings are accurate based on the literature since they are set to be in statute.
This bill: AB 2300 would prohibit beginning January 1, 2026, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution containers made with intentionally added DEHP. It would also prohibit, beginning January 1, 2031, a person or entity from manufacturing, selling or distributing into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions. Additionally, it would also prohibits a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates. Lastly, it would exempts human blood collection and storage bags and apheresis and cell therapy blood kits and bags, including integral tubing, from the provisions of the bill.
Arguments in support: According to California Black Health Network and Breast Cancer Prevention Partners:
"DEHP has been classified by the US Environmental Protection Agency as a Group B2, probable human carcinogen. The U.S. Food and Drug Administration has suggested manufactures consider eliminating the use of DEHP in certain devices that can result in high aggregate exposures in sensitive patient populations, and The American Medical Association, among other professional organizations, encourages hospitals and physicians to reduce and phase out the use of PVC medical device products, especially those containing DEHP.
Research indicates that DEHP promotes drug resistance and inhibits the effectiveness of breast cancer drugs; interferes with the ability of chemotherapies to fight breast cancer, and that patients with higher levels of DEHP in their system had higher rates of relapse and mortality.
DEHP also has impacts beyond human health. It leaches into the environment through the disposal of plastic waste in landfills. It sticks strongly to soil and breaks down slowly when it is near the surface. Indoors, DEHP can also stick to dust particles. DEHP stuck to particles in the air can return to the ground or bodies of water via rain or snow. DEHP does not usually evaporate into the air or easily dissolve in water. It can build up in fish and other water-dwelling species.
Our standards for medical devices, especially devices used by immunocompromised patients, need to be higher. DEHP is harmful throughout its entire life cycle, from manufacturing to disposal, and it has impacts beyond human health. We know that safer products exist, so why aren’t we using them? Non-DEHP containers and tubing have been available for decades. Just as DEHP is no longer allowed in toys and other children’s products, it is time for DEHP to be eliminated from these medical products."
Arguments in opposition: According to a coalition of industry stakeholders:
"Given the robust pre-market medical device and new drug application review process at the United States Food and Drug Administration (FDA), we are concerned with the precedent AB 2300 would set. Medical devices and drugs are distributed nationally, and the FDA regulatory process provides manufacturers, healthcare providers, and patients with a consistent set of rules governing product safety. It would be extremely difficult for the industry to navigate a patchwork of inconsistent state regulations governing medical devices and drugs.
Changing or substituting product materials is a highly complex process and subject to strict regulatory requirements and lengthy approval times. We respectfully request your consideration of two amendments that, despite concerns articulated above, would help alleviate concerns around patient safety and access.
- Delayed implementation: Given the robust manufacturing and FDA approval processes described above, we propose an effective date of 2035 for both Intravenous tubing and solution containers.
- Amending the definition of "Intentionally added DEHP" to include a 0.1% w/w threshold – this will allow manufacturers to test products to ensure compliance and is important to distinguish between intentional vs unintentional uses."
Related Legislation:
- AB 2244 (Ting, 2024). Prohibits, beginning on January 1, 2025 a paper proof of purchase (receipt), provided to a consumer by a business or created by a manufacturer, from containing bisphenol A (BPA) and would prohibit, beginning January 1, 2026, a paper proof of purchase, provided to a consumer by a business or created by a manufacturer, from containing any bisphenols. This bill is pending action in the Assembly Appropriations Committee.
- AB 418 (Gabriel, Chapter 17, Statutes of 2023). Prohibits, beginning January 1, 2027, a person or entity from manufacturing, selling, delivering, distributing, holding, or offering for sale, in commerce a food product for human consumption that contains any of the following: brominated vegetable oil, potassium bromate, propylparaben, and red dye 3.
- AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020). Prohibits, beginning January 1, 2025, prohibit a person or entity from manufacturing, selling, delivering, holding, or offering for sale, in commerce any cosmetic product that contains specified intentionally added ingredients. The list includes two phthalates: dibutyl phthalate (DBP, CAS no. 84-74-2) and diethylhexyl phthalate (DEHP, CAS no. 117-81-7).
- AB 1319 (Butler, Chapter 467, Statutes of 2011). Prohibits the sale, manufacture, or distribution of any bottle or cup that contains BPA, at a detectable level above 0.1 parts per billion (ppb), if the bottle or cup is designed or intended to be filled with any liquid, food or beverage intended primarily for consumption from that bottle or cup by children three years of age or younger.
- AB 1108 (Ma, Chapter 11, Statutes of 2007). Prohibits the manufacture, sale, or distribution in commerce of any toy or child care article that contains di-(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate (DBP), or benzyl butyl phthalate (BBP), in concentrations exceeding 0.1 percent. Prohibits the manufacture, sale, or distribution in commerce of any toy or child care article intended for use by a child under three years of age if that product can be placed in the child’s mouth and contains diisononyl phthalate (DINP), diisodecyl phthalate (DIDP), or di-n-octyl phthalate (DnOP), in concentrations exceeding 0.1 percent. Requires manufactures to use the least toxic alternative.
REGISTERED SUPPORT / OPPOSITION:
Support
A Voice for Choice Advocacy
Access Reproductive Justice
Alliance of Nurses for Healthy Environments
Asian Americans Advancing Justice Southern California
Association of Regional Center Agencies
B. Braun Medical, INC.
Breast Cancer Prevention Partners
Buen Vecino
California Black Health Network
California Health Coalition Advocacy
California Nurses for Environmental Health and Justice
California Pan-ethnic Health Network
CALPIRG, California Public Interest Research Group
Center for Community Action and Environmental Justice
Center for Environmental Health
Clean Production Action
Clean Water Action
Cleanearth4kids.org
Courage California
Defend Our Health
Educate. Advocate.
Health Care Without Harm
Health Equity for African American's League (HEAAL)
Healthy Contra Costa
Keep a Breast
Latino Coalition for A Healthy California
Made Safe
Mixteco Indigena Community Organizing Project
National Association of Environmental Medicine (NAEM)
National Stewardship Action Council
National Union of Healthcare Workers
Northern California Center for Well-being
Plastic Pollution Coalition
PRC/Black Leadership Council
Public Health Advocates
San Francisco Bay Physicians for Social Responsibility
Science and Environmental Health Network
Sharp Healthcare
The Last Beach Cleanup
Urban Strategies Council
Western Center on Law & Poverty, INC.
Women's Voices for The Earth
Young Invincibles
Opposition
Advanced Medical Technology Association (ADVAMED)
Cerus Corporation
Analysis Prepared by: Brenda Cisneros-Larios / E.S. & T.M. /
Date of Hearing: April 2, 2024
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 2300
Author:((Wilson) – As Amended Ver:March 6, 2024
AS PROPOSED TO BE AMENDED
SUBJECT: Medical devices: Di-(2-ethylhexyl) phthalate (DEHP).
SUMMARY: Prohibits a person or entity from manufacturing, selling, or distributing into commerce intravenous solution containers or intravenous tubing made with intentionally added di-(2-ethylhexyl) phthalate (DEHP). Specifically, this bill:
- Prohibits commencing January 1, 2026, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous solution containers made with intentionally added DEHP.
- Prohibits, commencing January 1, 2031, a person or entity from manufacturing, selling, or distributing into commerce in the State of California intravenous tubing made with intentionally added DEHP for use in neonatal intensive care units, nutrition infusions, or oncology treatment infusions.
- Prohibits a person or entity from replacing DEHP for revised or new products with other specified ortho-phthalates.
- Exempts the following items, as described in Title 21 of the Federal Code of Regulations, from the provisions of this bill: human blood collection and storage bags; apheresis and cell therapy blood kits and bags, including integral tubing.
EXISTING LAW:
- Prohibits a person or entity from manufacturing, selling, or distributing in commerce any toy or child care article that contains DEHP, dibutyl phthalate, or benzyl butyl phthalate, in concentrations exceeding 0.1%. [Health & Safety Code (HSC) § 108937]
- Requires manufacturers to use the least toxic alternative when replacing phthalates in products for young children. [HSC § 108939]
- Prohibits manufacturers from replacing phthalates in products for young children with carcinogens rated by the United States Environmental Protection Agency (EPA) as A, B, or C carcinogens, or substances listed as known or likely carcinogens, known to be human carcinogens, likely to be human carcinogens, or suggestive of being human carcinogens, as described in the “List of Chemicals Evaluated for Carcinogenic Potential,” or known to the state to cause cancer as listed in the California Safe Drinking Water Act. [HSC § 108939]
- Prohibits manufacturers from replacing phthalates in products for young children with reproductive toxicants that cause birth defects, reproductive harm, or developmental harm as identified by the EPA or listed in the California Safe Drinking Water Act. [HSC § 108939]
- Prohibits, commencing January 1, 2025, a person or entity from manufacturing any cosmetic that contains intentionally added DEHP. [HSC § 108980]
FISCAL EFFECT: None.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, “As a recent patient of the medical care system, I have first-hand knowledge related to the need for multiple infusions, with long durations, through medicines administered from IV bags. Each time you are potentially being exposed to a toxic material simply because we haven’t passed a law to ban this toxic material. There are alternatives, they are currently being used, and they aren’t more expensive. The State decided to ban the use of DEHP in kids’ toys, I think it is time to ban this from medical containers that allow leaching directly into our bodies- when we are most vulnerable. People should be focused on their healthcare, not whether the very life-saving procedure is exposing them to cancer and other terrible health impacts.”
- BACKGROUND.
- What are phthalates? According to the Centers for Disease Control and Prevention (CDC), phthalates are chemicals used in the manufacture of plastics, often called plasticizers. Phthalates can prolong the lifespan or durability of plastics and increase the flexibility of some plastics, and have been used as solvents for other materials. They are used in hundreds of products, including vinyl flooring, adhesives, detergents, lubricating oils, some pharmaceutical and pesticide formulations, and personal-care products, such as soap, shampoo, hair spray, and nail polish. Phthalates are also used in flexible polyvinyl chloride plastics, such as plastic bags, food packaging, garden hoses, inflatable recreational toys, intravenous tubing, automotive plastics, and plastic clothing, such as raincoats.
- Phthalates in medical products. DEHP is the phthalate most commonly used in medical products. Some medical products such as intravenous (IV) bags can contain up to 40% DEHP by weight. Every month, more than 40 million IV infusions are administered in the U.S. to treat dehydration, deliver medicines and nutrition, and for blood transfusions. More than 60% of the IV bags used in those infusions are made from DEHP. The phthalate leaches to varying degrees from medical devices during certain medical procedures and exposes the patient.
- Potential Impacts of Exposure to DEHP. According to the CDC, exposure to DEHP has been linked to decreased testosterone and sperm motility, preterm birth, altered timing of puberty, delayed mental development. The U.S. Department of Health and Human Services classified DEHP as reasonably anticipated to be a human carcinogen (a substance that can cause cancer in people). The EPA has determined that DEHP is a probable human carcinogen. The International Agency for Research on Cancer has classified DEHP as possibly carcinogenic to humans. Assessments conducted for the governments of the United States, Canada, and the European Union have all concluded that exposures to DEHP are of concern to some patient populations and subsets of the general public. In 2003, the state of California’s Office of Health Hazard Assessment listed DEHP as a reproductive toxicant under the Safe Drinking Water and Toxic Enforcement Act of 1986. In California, manufacturers and others who make or use products containing DEHP are now required to provide warnings to consumers that their products contain a chemical known by the state of California to cause reproductive toxicity. Research suggests that infants and toddlers, pregnant and lactating people, and patients undergoing certain medical procedures are especially vulnerable to DEHP exposure.
- Calls to label, reduce and phase out the use of DEHP.
- United States.
- In 2002, the federal Food and Drug Administration (FDA) issued draft guidance suggesting that manufactures label certain devices with their DEHP content and consider eliminating the use of DEHP in certain devices that can result in high aggregate exposures in sensitive patient populations.
- In 2006, the American Medical Association, among other professional organizations, encouraged hospitals and physicians to reduce and phase out the use of polyvinyl chloride (PVC) medical device products, especially those containing DEHP.
- The National Academy of Sciences in their 2008 report, “Phthalates and Cumulative Risk Assessment: The Task Ahead,” recommends that risks associated with phthalate exposure should be considered in the context of cumulative exposures to all phthalates and other anti-androgens. When infants, toddlers, fetuses, and pregnant people are exposed to DEHP from medical devices it adds to the already existing burden of chemicals that may also interfere with normal development of the reproductive tract. This highlights the concern for risk of harm from exposures to DEHP.
- European Union.
- In 2001, the European Parliament adopted a resolution in response to the Commission Green Paper on environmental issues of PVC and called for the Commission and the PVC industry to examine how targets might be set to reduce the use of phthalates, including DEHP, particularly in medical equipment. The resolution also asked the Commission to examine alternatives to the uses of phthalates as plasticizers.
- The Swedish Chemicals Inspectorate in its 2004 report for the European Union (EU) assessed the toxicity of DEHP for all human populations. It concluded that DEHP poses risks to many sub-populations, and that there is need for limiting the risks from DEHP exposure for human health for: newborns receiving transfusions, children receiving long-term blood transfusion or extracorporeal oxygenation, and adults receiving long term hemodialysis.
- In 2004, the German Federal Institute for Drugs and Medical Devices issued a warning to health care professionals in order to minimize exposure to DEHP primarily for high-risk patient groups. These include fetuses, premature infants and newborns, as well as children in pre-puberty age. It was recommended that: medical devices manufacturers actively engage and strive for further development of safer DEHP-free alternative products; manufacturers consequently provide users with a comprehensive explanation on the risks of DEHP in medical devices as well as label correspondingly their products; neonatal intensive care units use alternative products if available and suitable for the relevant procedure in order to act with precaution and therefore avoid DEHP exposure for premature infants and newborns.
- The EU’s 2005 draft Risk Reduction Strategy prepared by the Swedish Chemicals Inspectorate proposed a set of legislative actions to limit the risks of DEHP exposure to all vulnerable populations. The recommended actions include: the use of DEHP should be restricted in medical devices giving rise to exposure of newborns and groups identified to be of concern in the risk assessment report assuming availability of safe alternative.
- In February 2005, the European Parliament brought this issue again to the forefront by adopting a resolution on the European Environment & Health Action Plan 2004-2010. The resolution called for restricting the market and/or use of dangerous substances, including DEHP, in domestic products for indoor use and in medical devices, specifically for vulnerable groups, particularly newborn babies, children, pregnant people, elderly persons, workers, and other high-risk sections of the population that are heavily exposed.
- Under the new regulation (EU) 2023/2482, issued in November 2023, users of DEHP in medical devices will note that they will no longer be able to use DEHP from July 1, 2030, unless they apply for authorization before January 1, 2029.
- United States.
- Availability of non-DEHP alternatives in medical devices. Many manufacturers, including B. Braun, Fresenius Kabi USA, Baxter, and ICU Medical, advertise that they already provide products without DEHP.
- Per B.Braun Medical’s website: “More than 40 years ago, B. Braun recognized the environmental and patient risks posed by medical products containing PVC and DEHP. We were the first medical device manufacturer to remove these harmful substances from many of our products, and remain the only supplier offering a full line of IV drug and solution containers not made from PVC or DEHP.”
- Per Fresenius Kabi USA’s website: “Our freeflex and freeflex+ IV bags are designed with safety in mind. Studies have shown that PVC relies on and creates chemicals like DEHP that are highly hazardous to humans and the environment. For that reason, all freeflex IV bags are non-PVC and non-DEHP and can be used across the facility for the broadest clinical application.”
- Per Baxter’s website: "To meet the preferences of some customers and address drug compatibility issues in specific clinical applications, Baxter offers a portfolio of intravenous medications, parenteral nutrition solutions, injectable drugs, biopharmaceuticals, IV sets and access devices, and other products that use or are contained in non-PVC materials or non-DEHP [di-(2-ethylhexyl)phthalate], a common component of PVC materials."
- Per ICU Medical’s website: "With our broad portfolio of non-PVC, non-DEHP IV containers, you can get the container you need to meet the challenges of hazardous drug compatibility while helping with environmental and patient initiatives focused on phthalate reduction."
- The use of DEHP in blood bags. Commercial blood bags are predominantly made of PVC plasticized with DEHP. DEHP is favorable for storage of red blood cells (RBC). Historically, removal of DEHP from blood bags has been linked to unacceptable haemolysis levels. Oncoming regulatory restrictions for DEHP due to toxicity concerns increase the urgency to replace DEHP without compromising RBC quality. Research suggests that Di(2-ethylhexyl) terephthalate may be a suitable candidate for replacement of DEHP in blood bags in the future.
- SUPPORT. Breast Cancer Prevention Partners and California Black Health Network, cosponsors of the bill, state that research indicates that DEHP promotes drug resistance and inhibits the effectiveness of breast cancer drugs; interferes with the ability of chemotherapies to fight breast cancer, and that patients with higher levels of DEHP in their system had higher rates of relapse and mortality. California’s standards for medical devices need to be higher. DEHP is harmful throughout its entire life cycle, from manufacturing to disposal, and it has serious impacts that extend beyond human health. Non-DEHP containers and tubing have been available for decades. The cosponsors conclude that just as DEHP is no longer legally allowed in make-up and personal care products, toys and other children’s products sold in California, it is time for DEHP to be eliminated from these medical devices.
- SUPPORT IF AMENDED. Fresenius Kabi (FK), a health care company that provides products and services for blood infusion and transfusion, states that, at present, replacing DEHP in blood bags remains a scientific challenge worldwide as these products are highly effective at safeguarding the unique properties of blood and blood components, for periods of up to 49 days, against a wider temperature range and a higher degree of force and stress than IV solutions. Until non-DEHP blood products are developed and made widely and affordably available, FK recommends excluding them from this proposed bill. FK concludes that excluding them would have the unintended public health consequences of causing blood shortages in California and perhaps elsewhere as well.
- OPPOSE UNLESS AMENDED. The Advanced Medical Technology Association (AMTA) opposes unless amended. AMTA states that given the robust pre-market medical device and new drug application review process at the United States Food and Drug Administration (FDA), AMTA is concerned with the precedent this bill would set. Medical devices and drugs are distributed nationally, and the FDA regulatory process provides manufacturers, healthcare providers, and patients with a consistent set of rules governing product safety. AMTA argues that it would be extremely difficult for the industry to navigate a patchwork of inconsistent state regulations governing medical devices and drugs. AMTA notes that hanging or substituting product materials is a highly complex process and subject to strict regulatory requirements and lengthy approval times. AMTA requests an effective date for 2035 on the requirements for IV tubing and solution containers and amending the definition of “intentionally added DEHP” to include a 0.1% threshold to allow manufacturers to test products to ensure compliance.
- DOUBLE REFERRAL. This bill is double-referred, upon passage of this Committee, it will be referred to the Assembly Committee on Environmental Safety and Toxic Materials.
- RELATED LEGISLATION.
- AB 2066 (Reyes) would, commencing January 1, 2027, prohibit a person or entity from using methylene chloride in the process of decaffeinating coffee. AB 2066makes a violation of these provisions punishable by a civil penalty not to exceed $5,000 for a first violation and not to exceed $10,000 for each subsequent violation, upon an action brought by the Attorney General, a city attorney, a county counsel, or a district attorney. AB 2066 is pending a hearing in the Assembly Committee on Health.
- AB 2217 (Weber) would, commencing January 1, 2027, prohibit a person or entity from manufacturing, selling, delivering, distributing, holding, or offering for sale, in commerce a food product for human consumption that contains tianeptine. AB 2217 would make a violation of these provisions punishable by a civil penalty not to exceed $5,000 for a first violation and not to exceed $10,000 for each subsequent violation, upon an action brought by the Attorney General, a city attorney, a county counsel, or a district attorney. AB 2217 is pending a hearing in the Assembly Committee on Health.
- AB 2365 (Haney) would add kratom products, as defined, to the Sherman Food, Drug, and Cosmetic Law and require processors of kratom products to register with the Department of Public Health. AB 2365 would prescribe specified quantities of alkaloids present in kratom products and would establish labeling and packaging requirements. AB 2365 would require that kratom products be registered with the department annually, which would include certification by a laboratory specifying that the product meets certain qualifications. The bill would prohibit the sale of kratom leaf and kratom products to those under 18 years of age. By expanding the scope of a crime, the bill would create a state-mandated local program. AB 2217 is pending a hearing in the Assembly Committee on Health.
- PREVIOUS LEGISLATION.
- AB 2762 (Muratsuchi), Chapter 314, Statutes of 2020, prohibits, beginning January 1, 2025, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing specified intentionally added ingredients.
- AB 1108 (Ma), Chapter 672, Statutes of 2008, prohibits the use of phthalates in toys and childcare products designed for babies and children under three years of age.
- AMENDMENTS. To address stakeholder concerns related to the current availability non-DEHP blood bags, the author has proposed amendments to exempt blood bags and human blood cell apheresis kits from the provisions of the bill.
- POLICY COMMENTS. To address concerns related to the manufacturing and FDA approval process, the author may also wish to consider delaying the implementation of requirements for the IV tubing and solution containers and amending the definition of intentionally added DEHP to include a threshold allowing manufacturers to test products to ensure compliance.
REGISTERED SUPPORT / OPPOSITION:
Support
Breast Cancer Prevention Partners (cosponsor)
California Black Health Network (cosponsor)
A Voice for Choice Advocacy
Access Reproductive Justice
Alliance of Nurses for Healthy Environments
Asian Americans Advancing Justice Southern California
Association of Regional Center Agencies
B. Braun Medical INC.
B. Braun Medical, INC.
Buen Vecino
California Health Coalition Advocacy
California Nurses for Environmental Health and Justice
California Pan-Ethnic Health Network
CALPIRG, California Public Interest Research Group
Center for Community Action and Environmental Justice
Center for Environmental Health
Clean Production Action
Clean Water Action
CleanEarth4Kids.org
Courage California
Defend Our Health
Educate. Advocate.
Health Care Without Harm
Health Equity for African American's League (HEAAL)
Healthy Contra Costa
Keep a Breast
Latino Coalition for a Healthy California
Made Safe
Mixteco Indigena Community Organizing Project
National Association of Environmental Medicine (NAEM)
National Stewardship Action Council
National Union of Healthcare Workers
Northern California Center for Well-Being
Plastic Pollution Coalition
PRC & /Black Leadership Council
Public Health Advocates
San Francisco Bay Physicians for Social Responsibility
Science and Environmental Health Network
Sharp HealthCare
The Last Beach Cleanup
Urban Strategies Council
Western Center on Law & Poverty, INC.
Women's Voices for The Earth
Young Invincibles
Analysis Prepared by: Eliza Brooks / HEALTH / (916) 319-2097
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Environmental Quality
Senate Standing Committee on Health
Assembly Floor
Assembly Floor
Assembly Standing Committee on Environmental Safety and Toxic Materials
Assembly Standing Committee on Environmental Safety and Toxic Materials
Bill Author
Bill Co-Author(s):